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RÉSUMÉ
IDENTIFICATION ET ISOLEMENT DE CELLULES STROMALES 
MULTIPOTENTES DU MUSCLE SQUELETTIQUE HUMAIN
Par
Jennifer Downey 
Programme de Pharmacologie
Mémoire présenté à la Faculté de médecine et des sciences de la santé en vue de l’obtention 
du diplôme de maître ès sciences (M.Sc.) en Pharmacologie, Faculté de médecine et des 
sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada, J 1H 5N4
Le muscle squelettique humain est une source essentielle de cellules progénitrices 
ayant plusieurs applications thérapeutiques potentielles. Les cellules stromales 
mésenchymateuses du muscle squelettique humain (hmrMSCs) semblent être impliquées 
dans des pathologies telles l’ossification hétérotopique, la dégénérescence graisseuse et la 
fibrose. L’identification de la population cellulaire à l’origine de ces pathologies permettrait 
de mieux comprendre les mécanismes derrières celles-ci et aiderait à la création de 
traitements plus efficaces. Nous avons d’abord mis au point une méthode d ’isolement et 
déterminer des conditions de culture pour la prolifération et le maintien en culture de la 
fraction cellulaire adhérente dérivée du muscle squelettique humain. Par le biais de la 
cytométrie en flux et des marqueurs connus des cellules stromales mésenchymateuses 
(MSC), nous avons pu enrichir les cellules stromales multipotentes. Le potentiel 
ostéogénique, adipogénique et chondrogénique des populations cellulaires enrichies a été 
évalué par des essais de différenciation. La sous-population de cellules 
CD73+CD105+CD90' a montré une multipotence robuste sur les trois lignées étudiées. Des 
essais de différenciation clonale ont confirmés que les trois lignées obtenues proviennent 
tous d’un progéniteur multipotent commun. De plus, cette sous-population cellulaire avait 
la capacité de se différencier en cellule de gras brun, démontrée par une expression élevée 
d’UCPl au niveau génique et protéique suivant une stimulation continue avec le 
rosiglitazone (ROS). Ce résultat suggère que cette sous-population cellulaire pourrait 
également représenter un modèle pour l’adipogenèse vers le gras brun. La méthode 
d’enrichissement présentée représente une nouvelle technique afin d’obtenir des hmrMSCs. 
Elle semble prometteuse pour de futures applications cliniques employant ces cellules, étant 
donné qu’elles sont amplifiées dans un milieu défini permettant une reproductibilité inter­
laboratoire. De plus, les marqueurs de phénotype choisis pour l’enrichissement par 
cytométrie en flux sont bien conservés entre individus, limitant la variabilité inter-donneur.
Mots clés : Cellules stromales mésenchymateuses, Cytométrie en flux, Gras brun, Maladies 
dégénératives, Multipotence, Muscle squelettique humain
SUMMARY
IDENTIFICATION AND ISOLATION OF MULTIPOTENT STROMAL CELLS FROM
HUMAN SKELETAL MUSCLE
By
Jennifer Downey 
Pharmacology Program
Thesis presented to the Faculty o f medicine and health sciences for the completion o f the 
Master’s degree diploma [Maitre ès Sciences (M.Sc.)] in Pharmacology, Faculty of 
Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada,
J1H 5N4
Human skeletal muscle is an essential source o f various cellular progenitors with 
potential therapeutic perspectives. Muscle-resident mesenchymal stromal cells (mrMSCs) 
are thought to be involved in the development o f several regenerative disorders such as 
fatty degeneration, heterotopic ossification and fibrosis. Identifying the cell population 
responsible for these pathologies will help better understand the underlying mechanisms 
and lead to more efficient treatment. We first developed an isolation method and culture 
conditions for the prolifération and maintenance of the adhèrent fraction of human skeletal 
muscle derived cells. To further enrich the cell population as multipotent progenitors, we 
used fluorescent-activated cell sorting (FACS) and known mesenchymal stromal cell 
(MSC) markers. The enriched cell populations obtained were tested for their multipotent 
capabilities towards the ostéogénie, adipogénie and chondrogenic lineages. The 
CD73+CD105+CD90' subset of human skeletal muscle adhèrent cells displayed robust 
multipotence to ail three lineages under the appropriate différentiation conditions. Clonal 
différentiation assays confirmed that ail three lineages stem from a single multipotent 
progenitor. Furthermore, this cell subset was able to differentiate into brown adipocyte-like 
cells, expressing UCP1 at the RNA and protein levels following prolonged stimulation with 
rosiglitazone (ROS). This resuit suggests that this cell subset could also represent a human 
cell model for brown adipogenesis. The cell isolation and enrichment method presented in 
this thesis represent a novel technique to obtain human mrMSCs. This method holds great 
promise for future clinical applications with the enriched cell populations since they are 
expanded in a defined medium, which supports inter-laboratory reproducibility. 
Furthermore, the phenotypic markers chosen for the FACS isolation are well conserved 
amongst donors in the proposed conditions, limiting donor-to-donor variability.
Keywords: Brown adipogenesis, Fluorescent-activated cell sorting, Human skeletal muscle, 
Mesenchymal stromal cells, Multipotency, Regenerative disorders
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F o r e w a r d
Due to its marked regenerative capacity, skeletal muscle is one of the most studied 
tissues in regenerative biology. Despite significant advances in understanding the process 
of muscle tissue régénération after injury or disease, the identity o f the progenitor cells 
involved has been a matter of considérable debate, particularly with respect to regenerative 
disorders such as fibro/adipogenic degeneration and heterotopic ossification (HO).
Mesenchymal stromal cells (MSCs) are a population of multipotent adult progenitor 
cells with many properties that make them attractive for use in the field of regenerative 
medicine (Aldahmash et al. 2012). These cells are inherently plastic, enabling them to 
differentiate along différent lineages. They also appear to exhibit a number of trophic 
properties that promote régénération in the surrounding tissue (Caplan 2009). Furthermore, 
MSCs can be harvested from a variety of adult tissues (da Silva Meirelles et al. 2006), and 
of particular interest in this thesis from skeletal muscle (Huard 2008).
In spite of the potentially far-reaching promise o f MSCs in many aspects o f 
regenerative medicine, approaches using these cells are limited by the availability of a 
suitable MSC population in a clinical setting. Another obstacle arises from the 
identification of MSC populations due to a lack of standardization with respect to methods 
for their isolation and expansion.
This thesis focuses on the enrichment and characterization of a muscle résident 
stromal progenitor cell population from adult human skeletal muscle.
1. In t r o d u c t io n
1.1. Skeletal muscle tissue
Skeletal muscle is the largest tissue mass in the body, making up approximately 
40% of the total body weight (Huard et al. 2002). As a form of striated muscle tissue, its 
main function is to perform locomotor activity under the voluntary control o f the somatic 
nervous system. In addition, it is documented to have an important rôle in metabolism and 
its perturbation may contribute to metabolic diseases such as metabolic syndrome (Wells et 
al. 2008).
1.1.1. Structure o f skeletal muscle tissue
As the name suggests, most skeletal muscles are attached to the bones by tendons. 
Although skeletal muscle is composed primarily o f contractile material, notably muscle 
fibers, it is a composite tissue of blood vessels, connective tissue, and nerves. Several layers 
of connective tissue encompass the muscle. The outer layer, the épimysium, groups several 
fascicles that surround the entire muscle and extend into the muscles’ tendons. Each 
fascicle, made up of parallel myofibers, also called muscle fibers, is enclosed within the 
périmysium. The endomysium, also referred to as the basai lamina, is the connective tissue 
that surrounds each individual myofiber (Fig. 1.1). The later separates myofibers from the 
surrounding connective tissue through which blood vessels run to provide nutrition, nerves 
to induce fiber contraction, and muscle résident stromal cells which maintain tissue 
integrity (Gillies and Lieber 2011).
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Figure 0.1: Skeletal muscle structure and organization
Illustration showing the organization o f  the skeletal muscle. Each myofiber is enclosed in a basai 
lamina and arranged in functional units called fascicles encompassed within three connective tissue 
sheaths: the endomysium (surrounding myofibers), the périmysium (surrounding fascicles) and the 
épimysium (surrounding the muscle). The myofibers are also surrounded by an important vascular 
network which is represented by the pink blood vessels. This network is extensive however for 
clarity only a few vessels are shown in this illustration. The stromal cells (in blue) are suggested to 
be perivascular cells, which is illustrated by their proximity to the blood vessels. Adapted from 
(Trensz et al., unpublished)
The muscle fiber, is the functional cell o f skeletal muscle tissue. It is a syncytium 
originating from the fusion of hundreds o f myogénie progenitor cells (MPCs). Each 
myofiber has hundreds of nuclei in its periphery and is composed o f parallel myofibrils, 
which are composed of sarcomeres, the contractile unit of the muscle. It is the banding 
pattem of sarcomeres, an arrangement o f thick myosin and thin actin filaments that gives 
skeletal muscle its “striated” appearance (Fig. 1.2). It is this high level of micro- and 
macro-organization that enables optimal contraction, which allows the muscle to fulfill its 
primary function.
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Figure 0.2: Internai structure of a muscle fïber
Muscle fibers are made up o f  myofibrils, which contain actin and myosin filaments. Muscle fiber 
organization with A bands and 1 bands gives skeletal muscle its striated appearance. Adapted from 
Servier médical art (Servier 2010).
1.1.2. Satellite cells
The highly effective regenerative capacity o f adult skeletal muscle is attributed to a 
population of mononucleated myogénie stem cells called satellite cells (Biressi and Rando 
2010; Yin et al. 2013). These cells were first described by their anatomical localization 
beneath the basai lamina surrounding the plasma membrane of the myofiber 
(sarcolemma) (Mauro 1961) (Fig. 1.3). This location provides a unique microenvironment 
that maintains satellite cells in a quiescent state under normal conditions. However, 
following tissue damage, environmental eues activate these cells. Once activated, satellite 
cells proliferate before fusing with pre-existing myofibers, or they form entirely new 
myofibers as they undergo a terminal différentiation process (Charge and Rudnicki 2004). 
To simplify nomenclature, only quiescent cells are called satellite cells. Once these cells are 
activated, they are called myogénie precursor cells (MPCs) or myoblasts in vitro.
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Figure 0.3: The myofiber and its satellite cells
The muscle fiber is a multinucleated cell originating from the fusion of myogénie progenitor cells 
(MPCs). Satellite cells are found between the plasma membrane of the myofiber and the basai 
lamina which surrounds it. Normally quiescent, satellite cells are activated following muscle 
damage in order to regenerate the myofibers. (Grenier et al. unpublished).
Other than location, the identification of satellite cells relies on spécifie biomarkers. 
In adult skeletal muscle, the paired domain transcription factor Pax7 is the canonical 
biomarker for satellite cells (Seale et al. 2000; Morrison et al. 2006; Yablonka-Reuveni 
2011). It is specifically expressed in ail quiescent and proliferating satellite cells across 
multiple species, including humans (McLoon and Wirtschafter 2003). Although skeletal 
muscle normally has a slow turnover rate, following an important trauma, muscle tissue is 
capable o f a rapid and complété régénération (Charge and Rudnicki 2004).
1.2. Skeletal muscle régénération
Following damage, as is the case after intensive exercise or trauma, skeletal muscle 
has the remarkable ability to initiate a rapid and extensive repair process. It is one o f the 
few adult tissues that possesses this regenerative capacity. The régénération of mature 
skeletal muscle is a complex process composed of a degenerative and a regenerative phase 
involving satellite cells, MPCs, immune cells, and the remodeling of the connective tissue 
by myofibroblasts (Charge and Rudnicki 2004). The damage triggers changes in the 
satellite cells microenvironment, leading to their activation. Satellite cells respond to these 
changes by re-entering the cell cycle to both self-renew and to generate MPCs, which is a 
process o f asymmetric division, that will eventually undergo terminal différentiation and 
fuse with myofibers to repair damage (Wang and Rudnicki 2012). The process of myogénie 
repair by satellite cells and MPCs is carefully orchestrated by the expression of spécifie 
myogénie transcription factors (see section 1.2.2),
61.2.1. Degenerative phase
Muscle degeneration begins with necrosis o f damaged muscle fibers (Fig. 1.4). This 
event is initiated by increased myofiber permeability, which is reflected by increased 
plasma levels of intracellular myofiber proteins. Myofiber necrosis also activâtes the 
complément cascade and induces inflammatory responses (Orimo et al. 1991) resulting into 
the recruitment of circulating leukocytes at damage sites (Gute et al. 1998; Figarella- 
Branger et al. 2003). Neutrophils are the first inflammatory cells to infiltrate the damaged 
muscle (Fielding et al. 1993), followed by macrophages which become the prédominant 
inflammatory cells (Orimo et al. 1991). The presence of inflammatory cells is essential for 
the phagocytosis of tissue débris, however it is also responsible for the production of 
cytokines which are important for the initiation o f the second phase of the repair process 
(Bischoff 1997).
Figure 0.4: Muscle tissue régénération
Mouse skeletal muscle tissue régénération in a transverse section following a hematoxylin and eosin 
staining. The images represent muscles at days 0, 7, 14 and 28 following muscle damage 
(cardiotoxin injection). Muscle régénération is characterized by muscle fiber degeneration 
accompanied by inflammatory cell infiltration (7d). This is followed by muscle fiber repair by 
MPCs which fuse together to form new myofibers characterized by a small diameter and the 
presence of central nuclei (arrowhead) (14d). At day 28, most of the myofibers are mature and have 
regained their initial dimension. Their nuclei have also migrated back to the periphery from the 
center. (Grenier et al., unpublished).
1.2.2. Regenerative phase
The second phase of the repair process concems muscle fiber régénération. There are 
markers that distinguish satellite cells from proliferative and mature MPCs, such as 
transcription factors from the myogénie related factors (MRFs) family including MyoD,
7Myf5 and myogenin. As mentioned earlier, quiescent satellite cells are characterized by 
their expression of Pax7, and Myf5 to a lesser extent. The latter is an important factor in the 
management of the satellite cell pool contributing to muscle homeostasis (Kuang et al. 
2007). Interestingly, the deletion o f Myf5 induces muscle fiber hypertrophy and Myf5‘ " 
MPC prolifération (Gayraud-Morel et al. 2007; Ustanina et al. 2007). MyoD is the first 
sign of satellite cell activation and its expression rapidly increases following muscle 
damage. Mice déficient for MyoD have less muscle mass and présent delayed myogénie 
différentiation (Yablonka-Reuveni et al. 1999; White et al. 2000). Also following muscle 
damage, MyoD déficient mice show an accumulation o f MPCs in the site of the damage 
incapable of differentiating and fusing (Megeney et al. 1996). While MyoD and Myf5 
expression encourages satellite cells to differentiate towards the myogénie lineage (Fig. 
1.5).
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Figure 0.5: Key factors involved in myogénie différentiation
Muscle damage induces the activation, prolifération and différentiation of satellite cells in order to 
repair damaged muscle fibers or create new ones. These stages are regulated by spécifie 
transcription factors. Pax7 and Myf5 are expressed by quiescent, activated and proliferating satellite 
cells. MyoD is spécifie for proliferating MPCs and those beginning différentiation. During 
maturation and fusion MPCs express myogenin and MRF4. These transcription factors can be used 
as markers to identify the différentiation stage (Trensz et al., unpublished).
8Following the MPCs prolifération phase, myogenin is expressed during terminal 
différentiation and fusion. Myogenin expression enables MPCs to exit the cell cycle, 
through p21 expression. Unlike the other transcription factors discussed, the loss o f 
myogenin leads to severe skeletal muscle deficiencies, highlighting its essential rôle in the 
différentiation of MPCs during embryogenesis (Venuti et al. 1995). Myogenin is linked to 
muscle fiber fusion and maturation. The différentiation process is then completed by the 
activation of muscle spécifie proteins such as myosin heavy chain (MHC), the motor 
protein of muscles thick filaments, leading to functional muscle fibers. Histologically, 
newly formed myofibers are characterized by central nuclei (Charge and Rudnicki 2004). 
Once MPC fusion is complété, newly formed myofibers increase in size due to functional 
protein synthesis, and myonuclei move to the periphery of the muscle fiber (Fig. 1.4).
After injury, tissue régénération involves not only the replenishment or replacement 
of parenchymal cells but also that o f supporting structures including blood vessels, nerves, 
connective tissue and stromal cells. Little is known about how this network o f associated 
cells, notably MSCs, coordinates myofiber growth, homeostasis and repair in skeletal 
muscle.
1.3. Skeletal muscle regenerative disorders
Although tissue régénération is ensured by tissue-specifïc stem cells, efficient tissue 
repair requires activation of the surrounding stromal microenvironment, mainly a-smooth 
muscle actin (aSMA) positive myofibroblasts, to produce growth and survival factors, pro- 
inflammatory chemokines and components o f the extracellular matrix, such as collagens. 
However, inappropriate activation o f the stromal compartment can lead to persistence of 
aSMA+ collagen-overproducing cells, extracellular matrix (ECM) accumulation and 
overgrowth of fibrous and/or adipogénie tissue, thereby compromising tissue recovery and 
impairing function (Wynn 2008). Therefore, tissue repair culminâtes in either complété 
restoration of tissue integrity, defined as régénération, or in a process that leads to the 
génération of stromal structures that replace functional tissue, which I will entitle 
‘regenerative disorders’ in this thesis. The three most commonly occurring outcomes of
9regenerative disorders are fibrosis, fatty degeneration and heterotopic ossification (HO) 
(Fig 1.6).
The accumulation of these mature cell types in tissues that have failed to properly 
regenerate suggests that altérations in the function of muscle résident mesenchymal stromal 
cells (mrMSCs) may represent a common thread underlying regenerative disorders. Unlike 
MPCs, the identity of the stromal progenitor responsible for mesenchymal lineages in 
skeletal muscle remains unclear.
Skeletal Muscle
Tissue Résident MSCs
Heterotopic ^ 9  Fatty
Ossification c-c' Degeneration 
Fibrosis
Figure 0.6: MSCs and skeletal muscle regenerative disorders
During injury or disease skeletal mrMSCs can expand and provide trophic support for régénération 
and/or differentiate to produce fibrosis, fatty degeneration or HO, or a combination o f  these 
(Adapted from Pretheeban et al. 2012).
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1.3.1. Fibrosis and fatty degeneration
After chrome injury, muscle is often replaced by a mix of fibrous tissue and white 
adipocytes in a process termed fatty degeneration. This fibro/adipogenic infiltration 
compromises muscle function and alters the tissue microenvironment, potentially limiting 
the success of regenerative approaches.
Pathophysiologic fibrosis is a defining characteristic in most reparative disorders 
involving chronic inflammation (Porter et al. 2002). It is characterized by excessive 
accumulation of ECM in which collagen type I is the major component. It is the end resuit 
o f a cascade of events proceeding from tissue injury via inflammation, and resulting in 
permanent scar formation. The accumulated ECM replaces normal parenchymal tissue and 
can affect tissues and organ Systems, resulting in anatomical anomalies as well as reduced 
functional capacities. In skeletal muscle, fibrosis is most often associated with the muscular 
dystrophies. As well as the muscular dystrophies, aging is associated with loss o f skeletal- 
muscle mass and function with concomitant fibrosis and ECM déposition (Mann et al. 
2011).
The accumulation of fat in damaged tissue leading to “fatty degeneration” is another 
common regenerativedisorder (Moyer and Wagner 2011). Usually, fat is found in newly 
formed adipocytes infiltrating the tissue, most often associated with concurrent fibrotic 
matrix déposition, and associated with injuries and defective repair processes (Wallace and 
McNally 2009). The appearance of both fat accumulation and fibrosis has been shown in 
macrophage-suppressed mice (Warren et al. 2005; Segawa et al. 2008). Fat accumulation 
and fibrosis are also observed in mice lacking Myf5, a myogénie transcription factor 
(Gayraud-Morel et al. 2007). Furthermore, it is widely known that an increase in fatty and 
fibrous connective tissue is a hallmark o f advanced Duchenne muscular dystrophy (DMD), 
which is caused by a mutation of the dystrophin gene (Carpenter and Karpati 2001 ).
The poorly defined fibroblast or myofibroblast, the effector cell component o f 
connective tissue, is generally thought to be responsible for producing excessive collagen 
and other ECM proteins (Hinz and Gabbiani 2010). However, the origin o f fibrosis in
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skeletal muscle has not been elucidated (Mann et al. 2011). It has been suggested that both 
adipogénie and fibrogenic cells originate from myogénie cells through alternative lineage 
choices dictated by a pathological environment (Li et al. 2004; Shefer et al. 2004; Brack et 
al. 2007). As an example, muscle side population (SP) cells isolated from dystrophic or 
cardiotoxin-injured muscle, which normally contribute to myogenesis and muscle 
régénération, failed to undergo myogenesis and instead gave rise to fibroblasts and 
adipocytes (Penton et al. 2013), suggesting that muscle damage affects lineage choices of 
muscle SP cells for a possible rôle in fibrosis and fat déposition. The fate o f these 
progenitors is therefore heavily dépendent on their microenvironment. This local 
microenvironment dictâtes whether these cells provide trophic support to satellite cells, the 
endogenous myogénie stem cells, to yield complété régénération o f injured muscle or 
whether they generate the components of the fibro-fatty tissue infiltrâtes often found in 
degenerating muscle tissue. On the other hand, a population of skeletal muscle résident 
mesenchymal progenitors expressing platelet-derived growth factor receptor alpha 
(PDGFRof) has been shown to contribute to ectopic fat formation and fibrosis in mouse 
skeletal muscle under pathogenic conditions (Joe et al. 2010; Uezumi et al. 2011). Also, 
chronic activation of PDGFRa+ cells leads to widespread organ fibrosis in mice (Oison and 
Soriano 2009).
1.3.2. Heterotopic ossification
HO is another regenerative complication involving the formation of cartilage and 
bone outside o f the normal skeleton, within soft tissue such as muscle. Overall, it decreases 
range of motion and can cause partial or complété joint ankylosis for which surgical 
intervention is required. Usually, the development of HO is either genetic (Shore and 
Kaplan 2010) or acquired following a traumatic injury. (Vanden Bossche and 
Vanderstraeten 2005; Porter et al. 2007).
1.3.2.1. Fibrodysplasia ossificans progressiva 
The most severe form of HO is manifested in the rare, autosomal dominant genetic 
disorder, fibrodysplasia ossificans progressiva (FOP), in which heterotopic bone forms
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progressively throughout the life o f the individual, resulting in devastating effects on 
health, life expectancy, and quality of life (Kaplan et al. 2004; Vanden Bossche and 
Vanderstraeten 2005). It was discovered that FOP results from the missense mutations in 
the highly conserved glycine-serine (GS) regulatory domain of the bone-morphogenetic 
protein (BMP) Type I receptor 1 A/activin-like kinase-2 (ACVR1/Alk2) (Shore et al. 2006; 
Fukuda et al. 2009), which renders the BMP signalling pathway hypersensitive or 
independent o f BMP ligands (Shore et al. 2006; Billings et al. 2008; Fukuda et al. 2009). 
Injury is also a trigger for HO in FOP; however, in this genetically susceptible background, 
even mild soft tissue trauma can cause pronounced heterotopic skeletogenesis (Kaplan et 
al. 2008).
1.3.2.2. Traumatic heterotopic ossification
Traumatic HO is the most common type of HO, observed following fractures, bums, 
surgical traumas, especially total hip arthroplasty (THA) (Nilsson and Persson 1999). For 
example, HO is diagnosed on average in 53% of patients after THA. O f this number, 10% 
of patients suffer from severe HO with pain in the area o f the operated joint combined with 
a decrease in the range of motion, leading to functional impairment (Brooker et al. 1973; 
Thomas 1992). Not to mention, HO is also prévalent in patients with severe extremity 
wounds following a polytraumatic injury, in fact in these cases the incidence o f HO 
increases by 57% (Potter et al. 2007). The incidence of HO is also increased following 
central nervous system injuries (Newman et al. 1987; van Kuijk et al. 2002; Sakellariou et 
al. 2012). The range o f these conditions suggests that factors released by distant tissues 
such as the brain may have an osteoinductive effect on soft tissues either directly or by 
stimulating local cells to produce ostéogénie growth factors (Gautschi et al. 2009).
1.3.2.3. HO pathogenesis
Although the pathogenesis of HO is not fully understood, it is generally agreed that 
an inciting event, such as a trauma induces local inflammation (McCarthy and Sundaram
2005). This is followed by the recruitment o f surrounding ostéogénie progenitor cells that 
differentiate into chondrocytes, undergo hypertrophy and are replaced by endochondrale
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bone (Shore and Kaplan 2010). Therefore, HO is thought to resuit from the inappropriate 
différentiation of tissue résident ostéogénie progenitor cells that are induced by a 
pathological imbalance of local or systemic factors. However, the précisé cell origin and 
environmental eues leading to HO have not been fully elucidated. Since the most common 
cases of HO are in muscle and soft tissues (Nilsson and Persson 1999), it is important to 
understand the ostéogénie properties o f cells résident in skeletal muscle.
Among local tissue résident populations, satellite cells have received considérable 
attention as a possible cell-of-origin, primarily because of their muscle-restricted 
distribution and their capacity for BMP-dependent ostéogénie différentiation in culture 
(Katagiri et al. 1994; Wada et al. 2002). Cre/lox-based lineage analysis in the mouse, 
however, demonstrated that satellite cells in vivo do not appreciably contribute to HO 
lésions (Kan et al. 2009; Lounev et al. 2009).
1.4. Mesenchymal stromal cells
Friedenstein et al. was the first group to isolate multi-potential stromal precursor cells 
from the bone marrow (BM-MSCs). They described adhèrent, spindle-shaped, colony- 
forming unit fibroblasts (CFU-Fs) capable o f differentiating into adipocytes, chondrocytes 
and osteocytes both in vitro and after transfer in vivo (Friedenstein et al. 1974) (Fig. 1.7). It 
was subsequently demonstrated that these cells were also capable of multi-lineage 
différentiation at the clonal level (Pittenger et al. 1999). A clonal différentiation assay is 
important since it supports the hypothesis that the différentiation potential belongs to a 
single multipotent progenitor rather than unipotent subpopulations.
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Figure 0.7: Multipotent mesenchymal stromal cell characteristics
The plastic-adherent cellular fraction of many organs contains stromal progenitor cells that can give 
rise to colonies of fïbroblastic morphology. This cellular subset, known as CFU-Fs, can give rise to 
a proposed multipotent progenitor cell population, most probably heterogeneous in nature that 
résides in the perivascular location. Cultured under the appropriate conditions these cells can be 
expanded for multiple passages in vitro without losing their multipotent capabilities. The hallmark 
that defines MSCs is their ability to differentiate towards ostéogénie, adipogénie and chondrogenic 
cell fates under the appropriate stimuli. Différentiation into other non-mesenchymal mature cell 
types remains a matter of debate (adapted from Silberstein et al. 2011).
The regenerative benefit o f MSCs does not appear to correlate solely with their 
ability to differentiate into the diseased tissue type (Caplan and Dennis 2006). MSCs exert 
trophic fonctions in the environment o f damaged tissues that promote endogenous wound 
healing mechanisms (Caplan 2009), such as promoting angiogenesis (Tang et al. 2004; 
Martens et al. 2006), reducing fibrosis (Li et al. 2008; Mias et al. 2009) and modulating 
inflammation (Le Blanc et al. 2003; Kode et al. 2009). It has since been shown that MSCs
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also secrete trophic (pro-growth and pro-survival) factors that augment the endogenous 
régénération process (Tang et al. 2004; Lozito et al. 2009).
Therefore, multipotent mesenchymal stromal cells can be defined as a heterogeneous 
population of cells that proliferate in vitro as plastic-adherent cells, have fibroblast-like 
morphology, form colonies in vitro and can differentiate into bone, cartilage and fat cells 
(Horwitz et al. 2005). Since their original description, MSCs categorized based on 
trilineage (osteoblast, adipocyte and chondrocyte) potential in vitro have been isolated from 
the adhèrent fraction of many adult tissues in multiple species (da Silva Meirelles et al.
2006).
1.4.1. Tissue sources o f MSCs
In addition to bone marrow aspirate, MSCs have been isolated from a variety o f other 
adult tissues, including adipose tissue (Gimble and Guilak 2003; Meliga et al. 2007), skin 
(Toma et al. 2001), the marrow space of long bones (Kuo and Tuan 2003; Tuli et al. 2003), 
trabecular bone (Tuli et al. 2003; Song et al. 2005), synovial membranes (De Bari et al. 
2001), and periosteum (Nakahara et al. 1991; Choi et al. 2008) to name a few. However the 
limited availability of these tissues may limit their clinical potential. Similarly, MSCs have 
been harvested from tissues that are lost as a resuit o f development, such as the umbilical 
cord (Lee et al. 2004; Baksh et al. 2007) and umbilical cord blood/Wharton’s Jelly (Cetrulo 
2006; Troyer and Weiss 2008).
Of particular interest, there have also been several reports o f harvesting MSC-like 
cells from murine and human adult skeletal muscle. Human muscle tissue used to harvest 
cells was obtained from healthy muscle tissue biopsies (Zheng et al. 2007), surgical waste 
tissue from orthopaedic reconstructions, or surgically debrided muscle tissue following 
orthopaedic trauma (Nesti et al. 2008). Given that these cells can be obtained from surgical 
waste tissue or from minimally invasive biopsy procédures, there is growing evidence that 
skeletal muscle may be an important clinical source of MSCs for use in therapeutic 
applications.
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1.4.2. Identification o f MSCs
Identifying MSCs in vivo is difficult, due to their low abundance. Consequently, the 
majority of work studying the properties of MSCs has been performed using cultured 
MSCs which are selected by adhérence to tissue culture plastic, followed by différentiation 
assays to test their multilineage potential. This sélection method makes it difficult to 
compare MSC populations from différent species, isolation techniques, culture conditions, 
and donor sites.
Multipotence and adhérence to tissue culture plastic are important characteristics of 
MSCs, yet there is no définitive, agreed-upon marker to positively identifÿ a population 
that is capable o f these functions (Kolf et al. 2007). Instead, human MSCs are identified 
based on the expression of a number o f surface markers comprising CD105, CD90, CD73, 
CD71, CD44 and Stro-1 (Moroni and Fomasari 2013). Adhésion molécules like CD 166, 
CD 106, ICAM-1, and CD29 are also reported to be expressed on MSCs, while 
hematopoietic surface markers, such as CD45, CD34, CD 14 and CD11, are not. MSCs are 
also characterized by a négative expression of co-stimulatory markers like CD86, CD80, 
and CD40, as well as spécifie adhésion molécules related to platelet/endothelial cells 
(CD31 or PECAM-1), to neural adhésion (CD56), and to leukocyte function (CD18 or 
LFA-1) (Moroni and Fomasari 2013).
These markers were essentially developed for cells harvested from the bone marrow. 
Therefore, additional tissue-specific criteria may also apply to this cell population from 
other tissues. In fact, these surface markers are not homogeneously expressed throughout 
stromal cultures and they may vary with tissue source (Al-Nbaheen et a l 2013). This raises 
the question of whether MSCs from différent anatomical locations, selected by classic 
adhérence and in vitro culture methods are biologically équivalent.
Interestingly, MSCs derived from various embryonic and postnatal tissues using 
identical culture conditions display significant différences in colony forming morphology, 
différentiation potential and gene expression (Lee et al. 2004; Panepucci et al. 2004; da 
Silva Meirelles et al. 2006; Kaltz et al. 2010). Furthermore, studies have characterized and
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compared the immunophenotype of cultured adipose-derived stromal cells (ADSCs), in 
early and later passages, and found that the expression profile changes during culture time. 
It has been repeatedly shown that freshly isolated ADSCs express différent surface markers 
than those in later passages (Mitchell et al. 2006; Varma et al. 2007). Many of the markers, 
particularly surface proteins, may be differentially up- or down-regulated in vitro, possibly 
influenced by culture conditions such cell confluence and medium, which may be 
especially true when using serum-based culture medium.
1.4.3. Cell surface markers for MSCs
Although MSCs do not express unique phenotypic markers, the International 
Society for Cellular Therapy proposed minimal criteria (Dominici et al. 2006) for defîning 
MSCs based on their plastic adhérence, phenotype and trilineage multipotence in order to 
help standardize their identification amongst researchers. The phenotype définition requires 
the expression of CD73, CD90 and CD 105, together with a lack o f expression of 
haematopoietic progenitor and endothélial cell markers (CD34), a leukocyte marker 
(CD45) and several others markers spécifie for other cell types. However, these markers 
were identified in studies done using mostly human bone marrow MSCs and it is still to be 
determined whether they apply to human muscle-derived MSCs.
1.4.3.1. CD73
CD73 is an ecto-5’-nucleotidase, which is known to be involved in bone marrow 
stromal interactions (Barry et al. 2001), mesenchymal stem cell migration (Ode et al. 
2011), and potentially, MSC modulation of adaptive immunity (Eckle et al. 2007).
1.4.3.2. CD 105 (endoglin)
Several groups have reported the expression of the cell surface receptor CD105 
(endoglin) to be correlated with stem cell capacity within mesenchymal cells o f adipose 
tissue and bone marrow origin (Rada et al. 2011). Mechanistically, CD 105 has been shown 
to function as a TGFpl co-receptor (Castonguay et al. 2011; Zhang et al. 2011). CD105 has 
also been found to be involved in a variety of other biological processes. Studies have
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linked CD 105 to angiogenesis and neovascularization, the development o f pre-eclampsia, 
scleroderma, and psoriasis (Castonguay et al. 2011; Holmes et al. 2011; Nassiri et al. 
2011; Pohl et al. 2011)
1.4.3 3. CD90 (Thy-1)
CD90 (Thy-1) is a glycosyl-phosphatidylinositol (GPI)-linked membrane protein 
which has been shown to be associated with osteoprogenitor cells (Chen et al. 1999; Chan 
et al. 2009; Nakamura et al. 2010). CD90 is a member o f the immunoglobulin (Ig) 
supergene family and is also expressed on the surface of thymocytes, peripheral T cells, 
fibroblasts, épithélial cells, neurons, and hematopoietic stem cells (Reif and Allen 1964; 
Blankenhom and Douglas 1972; Williams 1982). Interestingly, CD90 expression varies 
with species (Dalchau and Fabre 1979; Kemshead et al. 1982) as well as the State of 
différentiation (Chen et al. 1999).
1.4.4. Multilineage potential o f  MSCs 
Beyond their ability to generate osteoblasts, adipocytes and chondrocytes in vitro, 
MSCs give rise to bone and cartilage after ectopic implantation in vivo (Ashton et al. 1980; 
Haynesworth et al. 1992) and have been documented to contribute to bone régénération in 
animal models of genetic bone disorders (Li et al. 2010).
Many studies have further reported MSC différentiation into multiple other cell types 
o f mesodermal and non-mesodermal origin, including endothélial cells (Oswald et al. 
2004), cardiomyocytes (Makino et al. 1999), hépatocytes (Snykers et al. 2009) and neural 
cells (Phinney and Prockop 2007; Arthur et al. 2008). Although the multipotent capabilities 
o f MSCs are controversial, their différentiation into the ostéogénie, adipogénie and 
chondrogenic lineages are now widely accepted and well documented.
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1.4.4.1. Osteoblastic différentiation
Osteoblasts develop through a sériés o f phases, initiated by cellular prolifération, 
followed by ECM déposition and matrix mineralization. This process o f cell maturation can 
be induced in vitro by the addition of BMPs, such as BMP2 (Diefenderfer et al. 2003), or 
the addition of a différentiation cocktail o f dexamethasone, ascorbate and (3- 
glycerophosphate (Jaiswal et al. 1997). A range o f transcription factors are known to be 
involved in the régulation of ostéogénie différentiation (Marie 2008), with the two most 
popular being runt-related transcription factor 2 (Runx2/Cbfal) and Osterix (Osx). Runx2 
is considered the major transcription factor controlling osteoblast commitment and 
différentiation. It is expressed early in skeletal development and throughout osteoblast 
différentiation. Osx, another important transcription factor involved in osteoblast 
commitment, appears to act downstream of RunX2. Osx is thought to act in the régulation 
of numerous osteoblast genes including, osteocalcin (OC). The latter is a bone spécifie 
protein synthesized by osteoblasts and represents a good marker for ostéogénie maturation 
(Nakamura et al. 2009).
1.4.4.2. Adipogénie différentiation
Adipocytes mature though a sériés of increasingly committed cell types, before 
expressing adipocyte spécifie markers such as fatty acid binding protein 4 (FAB4) (Samulin 
et al. 2008) and forming lipid vesicles which can be detected by oil red O staining. 
Peroxisome proliferator activated receptor-y (PPARy) is a nuclear hormone receptor, 
thought to be the master regulator of adipogenesis. There are two isoforms of PPARy, 
PPARy 1 is ubiquitously expressed whilst PPARy2 is restricted to adipose tissues and 
appears to be a more potent stimulator of adipogenesis (Mueller et al. 2002). PPARy is 
expressed early in the différentiation o f adipocytes, with forced overexpression of PPARy 
inducing adipogenesis in cultured fibroblast (Tontonoz et al. 1994).
1.4.4.3. Chondrogenic différentiation 
Chondrogenic différentiation in vivo requires an initial condensation of the MSCs, 
which is mimicked in vitro by culturing MSCs as micromass pellets. Chondrogenic
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différentiation can then be induced by the presence of transforming growth factor-p (TGFP) 
resulting in the appearance of a chondrocyte-like phenotype characterized by the up- 
regulation of cartilage-specific molécules such as collagen type II and IX, aggrecan, 
versican, biglycan and decorin (Pelttari et al. 2008). Chondrocyte maturation evolves 
though a sequence of defined steps; initially differentiating cells are termed chondroblasts 
and are proliferative. This stage is then followed by a hypertrophie stage, marked by the 
expression of collagen type-X, which is vital in vivo for vascular invasion, osteoblast 
différentiation, and bone formation. Sox9 is a high-mobility group box-containing 
transcription factor and is considered the master regulator o f  chondrogenesis. The Sox9 
gene is expressed in ail chondrocyte progenitors and chondrocytes, but its expression is 
completely tumed off in hypertrophie chondrocytes (Zhao et al. 1997). This expression 
parallels that of the gene for type II collagen (Col2al), a spécifie marker of chondrocyte 
différentiation.
1.5. Skeletal muscle résident mesenchymal stromal cell populations
It was originally suggested that satellite cells had the ability to differentiate into 
lineages other than the myogénie lineage, but recent studies have demonstrated that they are 
committed to the myogénie lineage and do not spontaneously adopt non-myogenic fates 
(Starkey et al. 2011). Also, several reports suggest that stem/progenitor cell populations 
other than satellite cells participate in skeletal muscle repair/regeneration. Several groups 
have identified muscle-resident mesenchymal progenitor cells with varying levels o f 
multipotency from mouse and human skeletal muscle. Interestingly, ail these described 
populations share a common characteristic: to be closely associated with small blood 
vessels within the interstitial tissue (Crisan et al. 2008; Crisan et al. 2012). Importantly, one 
must keep in mind that most o f the différent published sub-populations may be directly 
related to each other and/or share a common progenitor although they were not isolated and 
cultured the same way. Below are the main muscle résident mesenchymal progenitors 
described to date.
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1.5.1. Pericytes
Pericytes are defmed by their location, closely encircling endothélial cells in small 
vessels and capillaries (Andreeva et al. 1998). Recent studies suggest that pericytes include 
progenitors of différent cell types, capable o f differentiating along several lineages 
including ostéogénie and chondrogenic (Collett and Canfield 2005). However these 
populations represented pericyte-containing cultures and not purified pericytes. Dellavalle 
et al. demonstrated that pericytes sorted from human skeletal muscle based on alkaline 
phosphatase (AlkP) expression are myogénie precursors, distinct from satellite cells, which 
support skeletal muscle régénération (Dellavalle et al. 2007). Also, AlkP+ pericyte-derived 
cells can differentiate into osteoblasts and adipocytes in vitro.
Pericytes were sorted from multiple human organs, including fetal and adult skeletal 
muscle, by FACS. These perivascular cells were identified and sorted based on CD146+ 
expression, whereas contaminating myogénie (CD56+), hematopoietic (CD45+) and 
endothélial (CD34+) cells were eliminated. Sorted human perivascular cells (CD146+CD56' 
CD45'CD34') expressed recognized markers of mesenchymal stem cells, including CD73, 
CD90 and CD105. Additionally, these cells can be expanded in vitro. Also, when cultured 
in appropriate inductive conditions, the sorted perivascular cells differentiated into 
chondrocytes, adipocytes and osteocytes at the clonal level in vitro and developed into bony 
nodules when transplanted into a skeletal muscle pocket in a murine model (Crisan et al. 
2008).
1.5.2. Muscle-derived stem cells (MDSCs)
Murine skeletal muscle contains a population of stem cells termed muscle-derived 
stem cells (MDSCs) (Qu-Petersen et al. 2002). MDSCs are isolated from the muscle 
homogenate using a pre-plating technique, which éliminâtes the contaminating more 
adhèrent cell types (Gharaibeh et al. 2008). The more slowly adhèrent MDSCs have 
demonstrated enhanced différentiation potential, and can be induced to become osteoblast, 
adipocytes and chondrocytes in vitro. Also, these MDSCs have the ability to differentiate 
into myoblasts in vitro and to promote muscle régénération in vivo. Interestingly, a
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comparable population of MDSCs has not been harvested from human muscle tissue solely 
on the basis of their adhésion characteristics.
1.5.3. Myoendothelial cells (MECs)
In addition to satellite cells (CD56+) and endothélial cells (CD34+CD144+), human 
skeletal muscle contains a rare (<0.5%) population of cells that coexpress myogénie and 
endothélial cell markers (CD56+CD34+CD144+), which has been identified using FACS to 
isolate the cells that are positive for CD56+CD34+CD144+. Myoendothelial cells (MECs) 
proliferate long term, retain a normal karyotype, and survive better under oxidative stress 
than myogénie (CD56+) cells. Although most satellite cells are committed to the myogénie 
lineage, the small subset of satellite cells that co-expresses the endothélial markers is 
capable o f multilineage différentiation into myogénie, chondrogenic, and ostéogénie cells 
in vitro. Also, these cells appear to have enhanced myogénie potential in vivo, participating 
in myofiber régénération. MECs are associated with the vasculature in human skeletal 
muscle, specifically located in the intimai compartment of blood vessels within human 
skeletal muscle (Zheng et al. 2007).
A major limitation in characterizing the multipotent potential o f MECs was the likely 
heterogeneous nature in “stemness”, therefor it was investigated whether chondrogenic and 
ostéogénie potential was preserved at the clonal level. Clonal myoendothelial cells 
(cMECs: CD56+CD34+CD144+CD45') were purified (from ffesh human muscle biopsies by 
FACS. cMECs displayed robust multipotency in vitro and in vivo (Zheng et al. 2013), 
including chondrogenesis, osteogenesis, and adipogenesis, in addition to myogenesis. 
cMECs seem to represent a human counterpart of murine MDSCs, as one o f the 
multilineage mesodermal stem cell populations residing in the vascular niche within the 
adult skeletal muscle.
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/. 5.4. Skeletal muscle mesenchymal progenitors
The PDGFRa was used to identify mesenchymal progenitors in adult skeletal muscle, 
responsible for ectopic fat cell formation (Uezumi et al. 2010). PDGFRa+ mesenchymal 
progenitors are distinct from satellite cells and are located in the muscle interstitium. The 
expression of PDGFRa appears to be a characteristic of undifferentiated MSCs (Bail et al.
2007). According to Uezumi et al., of the muscle-derived cell populations, only PDGFRa+ 
cells show efficient adipogénie différentiation both in vitro and in vivo (Uezumi et al.
2010). In a subséquent study, it was shown that PDGFRa+ mesenchymal progenitors could 
also differentiate into ECM-producing cells. Clonal analysis showed that these cells possess 
the ability to differentiate into both collagen type-I-producing cells and adipocytes (Uezumi 
et al. 2011).
Moreover, murine fibro/adipogenic progenitors (FAPs) sorted by FACS (Lin’a7'Sca- 
1+) efficiently generate both fibroblasts and adipocytes at the clonal level, but fail to 
generate other mesenchymal lineages. Interestingly, Lin'a7‘Sca-l+ cells were uniformly 
PDGFRa+ (Joe et al. 2010).
Recent lineage tracing studies have implicated the vascular endothélium in HO, as 
cells expressing the angiopoietin receptor, Tie2, robustly contribute to ail stages of BMP- 
induced skeletogenic lésions (Lounev et al. 2009; Medici et al. 2010). A population of 
Tie2+PDGFRa+Scal+ cells was identified as multipotent mesenchymal progenitors that 
résidé in the murine skeletal muscle interstitium and represent a significant cell of origin for 
HO. These progenitors résidé in the interstitium o f skeletal muscle and other tissues, and 
are distinct from the endothélium. Intramuscular transplantation, together with clonal 
analysis in culture, revealed that these progenitors are multipotent, exhibiting the capacity 
for both BMP-dependent skeletogenic différentiation and spontaneous adipogénie 
différentiation (Wosczyna et al. 2012).
Recently, a group suggested that PDGFRa+ mesenchymal progenitors residing in 
human skeletal muscle are the major cell origin o f HO. In this study, both CD56+ myogénie 
cells and PDGFRoC mesenchymal progenitors showed comparable ostéogénie
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différentiation potential in vitro. However, in an in vivo ectopic bone formation model, only 
PDGFRa+ cells formed bone-like tissue and showed successful engraftment (Oishi et al. 
2013)
1.5.5. Muscle-resident stromal cells (mrSCs)
Our laboratory identified and isolated a population of murine muscle-resident stromal 
cells (mrSCs) which are also closely associated with the vasculature (Scime 2005, Leblanc
2011). The common stromal cell marker Seal was used to identify the mrSC population, 
whereas hematopoietic (Lin+) and endothélial (CD31) cell lineages were discarded. 
Depending on their culture conditions, this cell population took on an endothélial (Grenier 
et al. 2007), an adipogénie (Scime et al. 2005), a fibrogenic (Trensz et al. 2010) or an 
ostéogénie fate (Leblanc et al. 2011). This subpopulation is also augmented in chronic 
(Trensz et al. 2010) and acute muscle damage (Grenier et al. 2007; Leblanc et al. 2011), a 
condition which is known to lead to fibrosis and fatty degeneration. Not only are they 
known to express RunX2 and AlkP during ostéogénie différentiation in vitro, mrSCs have 
been shown to contribute to HO in vivo in a murine model for HO which consisted of 
injecting BMP9 within a damaged muscle (Leblanc et al. 2011).
1.5.6. Traumatized muscle mesenchymal progenitor cells
A population of multilineage mesenchymal progenitor cells was identified in human 
traumatized muscle, capable of undergoing ostéogénie différentiation in vitro (Nesti et al.
2008). These cells were isolated and enriched from digested muscle tissue based on their 
high adhésion characteristics to tissue culture plastic. Moreover, they have a cell surface 
epitope profile that is characteristic o f BM-MSCs (Jackson et al. 2009), although they 
appeared to demonstrate limited lineage commitment compared to their bone marrow 
counterparts. It was shown that damage triggers the activation and prolifération of a higher 
number of progenitors within muscle and that those cells were more responsive to 
ostéogénie eues (Jackson et al. 2011)
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The ongoing research is focused on improving skeletal muscle régénération, and 
limiting regenerative disorders, by investigating the hypothesis that cells related to the 
vascular wall in muscle tissue can (under appropriate conditions) give rise to potent “stem” 
cells that possess strong multilineage potential. For the time being, there is a lack of 
consensus in the field on the appropriate MSC isolation technique, caused largely by the 
absence of a truly sélective and universally adopted MSC marker, especially in human 
skeletal muscle.
Table 1: Summary of the différent mesenchymal progenitor cell populations described 
from skeletal muscle
Name Species Enrichment Localization Lineagepotential Reference
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1.6. Other skeletal muscle progenitor populations
1.6.1. Brown adipocytes
Humans have two types of adipose tissue: white adipose tissue (WAT), which not 
only stores energy in the form o f triglycérides but is also recognized as an important 
endocrine and immune organ, and brown adipose tissue (BAT), which is specialized in 
energy expenditure by buming lipids to generate heat (thermogenesis). While WAT 
structure is characterized by a single, large, lipid droplet in vivo and few mitochondria, 
BAT contains several small lipid droplets (multilocular), many mitochondria, and uniquely 
expresses high levels of uncoupling protein 1 (UCP1) (Cannon and Nedergaard 2010; 
Nedergaard et al. 2010; Richard and Picard 2011). UCP1 is a proton channel of the inner 
mitochondrial membrane that allows proton influx into the mitochondrial lumen. UCP1 acts 
to uncouple oxidative phosphorylation from ATP production, thereby releasing energy as 
heat (termed thermogenesis). BAT plays a pivotai rôle in adaptive thermogenesis, a 
physiological process during which energy is dissipated in response to environmental 
changes, such as cold température and diet (Lowell and Spiegelman 2000).
1.6.1.1. Origin o f  BA T
It has been suggested that BAT and skeletal muscle may share a common 
developmental ancestry (Timmons et al. 2007) . Myf5-expressing progenitors can give rise 
to both skeletal muscle and interscapular brown fat (Seale et al. 2008). In accordance with 
these observations, BAT progenitors have also been identified in human skeletal muscle 
(Crisan et al. 2008). These cells provide the potential for increasing the oxidative capacity 
of these tissues by targeting these endogenous precursor cells to differentiate in vivo into 
energy-dissipating brown adipocytes. Though, it is now clear that two différent types o f 
brown adipocytes exist, which have distinct developmental origins. Classical brown 
adipocytes residing in the interscapular and perirenal régions develop from 
myofibroblastic-like Myf5-positive precursors (Seale et al. 2008) that differentiate into 
brown adipocytes through the action o f transcriptional regulators PRDM16 and C/EBPb 
(Kajimura et al. 2009); whereas, pockets of a second, distinct type o f UCP1-positive
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adipocyte are found sporadically in the WAT of adult animais that have been exposed to 
chronic cold or p-adrenergic stimulation. These inducible brown-like adipocytes (beige or 
brite cells) possess many of the biochemical and morphological characteristics of classical 
brown adipocytes, including the presence of multilocular lipid droplets (Frontini and Cinti 
2010). However, they arise from a non-Myf5 cell lineage, hence, have a distinct origin. 
Also, it has been shown that epidydimal WAT-derived brite cells that are induced by 
rosiglitazone (ROS) do not express myocyte-enriched genes (Petrovic et al. 2010).
1.6.1.2. Factors regulating human brown adipogenesis 
Among factors regulating human brown adipogenesis, most of them have been 
identified and characterized in mouse models in vitro as well as in vivo. Within these 
signaling pathways, Hedgehog and BMP7 were described as modulators of brown 
adipogenesis (Tseng et al. 2008; Pospisilik et al. 2010; Schulz et al. 2011). When tested on 
human multipotent adipose derived stem cells (hMADs) as a model for brown 
adipogenesis, both Hedgehog and BMP7 did not have any significant effect on hMADs 
“brite” conversion, indicating discrepancies between mouse and human brown adipocyte 
régulation (Pisani et al. 2011). However, it has been shown that the activation o f PPARy by 
synthetic ligands induces a brown fat-like gene program in WAT (Fukui et al. 2000; Sell et 
al. 2004; Rong et al. 2007; Petrovic et al. 2010). Among members o f the thiazolidinedione 
family, ROS is known as a high-affinity ligand of PPARy. Mechanistically, these drugs 
function by directly binding to and activating PPARy and PPAR-response elements (PREs) 
on the promoter and/or enhancer o f brown fat-selective genes (Sears et al. 1996; 
Viswakarma et al. 2007).
Recent research has also identified several dominant transcriptional regulators of 
brown adipocyte development and function, including peroxisome proliferator activated 
receptor gamma coactivator la  (PGC1 alpha) and PRD1-BF-1-RJZ1 homologous domain 
containing protein-16 (PRDM16) (Kajimura et al. 2010). PG C -la is highly expressed in 
BAT compared with WAT and is responsible for regulating mitochondrial biogenesis and 
thermogenesis. Mice déficient in PG C -la are cold-sensitive with low expression of UCP1 
and a morphologically abnormal BAT (Lin et al. 2004). It is generally accepted that PGC-
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la  is the critical regulator of adaptive thermogenesis in responsive tissues. PRDM16 on the 
other hand is a 140-kDa zinc-finger PR domain-containing protein that induces a program 
of gene expression as well as mitochondrial biogenesis/oxygen consumption, consistent 
with the brown phenotype, when ectopically expressed in white preadipocytes in culture or 
white dépôts in the animal (Seale et al. 2007). Also, PPARy functions to regulate the 
underlying adipogénie programs common to both white and brown adipocytes. It is 
possible that its activity can favor one phenotype over the other. Several recent studies have 
shown that exposure of white adipocytes, either in culture or in animais, to potent PPARy 
ligands such as ROS induces a “browning” of the white cells, as characterized by an 
increase in mitochondrial mass and structure as well as a markedly enhanced oxygen 
consumption and lipid oxidation (Wilson-Fritch et al. 2003; Wilson-Fritch et al. 2004). 
This process is likely due to PPARy ligand-associated induction of mitochondrial genes, 
including UCP1 and cytochrome c oxidase (Cox) (Wilson-Fritch et al. 2004).
1.6.1.3. Adult BAT
In humans, BAT is présent in abundant quantity in newboms (Lean et al. 1986), but it 
was traditionally believed that BAT was nonexistent or non-functional in adult humans. 
However, this dogma was reversed by evidence from nuclear medicine (Nedergaard et al. 
2007; Cypess et al. 2009; Saito et al. 2009; van Marken Lichtenbelt et al. 2009; Virtanen et 
al. 2009), which showed active BAT in adult humans. Indeed, fluorodeoxyglucose (18F- 
FDG) positron émission tomography (PET) studies allowed visualization in humans of 
highly dynamic adipose tissue dépôts. Their metabolism was stimulated by cold. These 
dépôts were proposed to represent BAT that had been undetected until now (Nedergaard et 
al. 2007). Since then, there has been a flurry o f new data surrounding BAT function and 
therapeutic potential (Enerback 2010; Ravussin and Galgani 2011; Muller and Bosy- 
Westphal 2013).
1.6.1.4. Brown adipocyte progenitor populations in skeletal muscle
In adult humans, it remains to be determined which population of progenitors gives 
rise to brown fat. Although a group identified a subpopulation of adipogénie progenitors
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(Sca-l+/CD457Macl'; referred to as Sca-1+ cells) residing in murine brown fat, white fat, 
and skeletal muscle. These Sca-1+ cells from skeletal muscle and subcutaneous white fat 
are highly inducible to differentiate into brown-like adipocytes upon stimulation with 
BMP7 (Schulz et al. 2011).
1.6.2. Myofibroblasts
Following tissue injury, fibroblasts are recruited during the inflammatory phase of 
tissue régénération. These cells are then activated and acquire a smooth muscle cell-like 
phenotype; they are consequently called myofibroblasts. These myofibroblastic cells 
synthesize and deposit ECM components. They also exhibit contractile properties, due to 
the expression of a-smooth muscle actin (aSMA) in microfilament bundles or stress fibers, 
playing a major rôle in the contraction and maturation of the granulation tissue (Hinz 
2010). The presence of aSMA represents the most reliable marker o f the myofibroblastic 
phenotype (Tomasek et al. 2002). During the final phase o f healing, proteolytic enzymes, 
essentially matrix metalloproteinases (MMPs) and their inhibitors (tissue inhibitor o f 
metalloproteinases [TIMPs]) play an essential rôle. Following which the number of 
vascular cells and myofibroblasts is dramatically reduced by the process o f apoptosis 
(Desmouliere et al. 1995). Persistent fibrosis is often due to an imbalance between ECM 
synthesis and dégradation by myofibroblasts due to chronic inflammation.
1.6.2.1. TGFfil and myofibroblastic différentiation
Several cytokines and growth factors have a rôle in wound healing. Among these, 
TGFpl is a potent inducer of myofibroblastic différentiation (Desmouliere et al. 1993). 
Beyond induction of aSMA expression, TGF(31 also promotes the déposition of large 
amounts of ECM and reduces MMP activity by promoting TIMP expression (Micallef et al.
2012). Hence, TGFpi plays a key rôle in inducing the formation of fibrotic tissue that 
limits muscle healing after severe injury.
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1.6.2.2. Myofibroblast identification 
One limitation that has hindered studies o f fibrosis is the lack of good markers to 
label fibroblasts/myofibroblasts. It is well established that in non-muscle Systems, activated 
fibroblasts may be identified by their increased prolifération, migratory ability, enhanced 
contractility, increased expression of vimentin and, in particular, aSMA, a contractile 
protein of stress fibers. When aSMA stress fîbers contract, they exert mechanical tension 
on the ECM, which in tum provides a mechanically résistant support, hence the name 
“myofibroblast”. These cells are associated with tissue repair and fibrosis in many tissues 
and organs, including muscle, skin, liver, lung, bone and cartilage (Hinz et al. 2007). 
However, despite their relevance in these diseases, it remains unclear whether 
myofibroblasts are présent in fibrotic skeletal muscle, or whether they are instead mature 
fibroblasts actively producing ECM components (Lieber and Ward 2013). The 
identification of the myofibroblastic progenitor in skeletal muscle would help détermine 
their rôle in fibrosis.
2. H y p o t h e s is
The identity and régulation of the multipotent progenitors residing within the skeletal 
muscle are topics of great interest and intense study. Developing a method to obtain an 
enriched muscle résident stromal cell population from human skeletal muscle would help 
understand their rôle during normal skeletal muscle régénération as well as the mechanisms 
behind their aberrant activation during regenerative disorders. Furthermore, the multipotent 
capabilities of these cells also make them excellent candidates for potential applications in 
cellular therapy and/or tissue engineering.
We believe that FACS can be used as an efficient enrichment method, to isolate the 
stromal subpopulation from the adhèrent fraction o f human muscle-derived cells by using 
multiple mesenchymal stromal cell markers identified in other tissue sources. We propose 
that these markers will enable the identification of the human mrMSC subset as they do in 
other tissue sources and enable the isolation o f a cell subpopulation with superior 
multipotent capabilities. Furthermore, we propose that a defined culture system that enables 
the prolifération and maintenance of these cells in culture will be more compatible with 
future applications and foster inter-laboratory reproducibility.
To test this hypothesis, we have established three objectives:
3. O b j e c t iv e s
1) Develop a reproducible enrichment strategy for the isolation and the culture o f the 
adhèrent human muscle résident mesenchymal stromal cell fraction
2) Identify the multipotent stromal cell subpopulation
3) Characterize other progenitor populations présent in human skeletal muscle
4. MATERIAL AND METHODS
4.1. Human adult skeletal muscle samples
Healthy human muscle tissue (gracilis and semitendinosus) (Fig. 4.1) was obtained 
from patients (mean âge, 32 years; range, 18 to 48 years; 56% maie and 44% female) 
undergoing anterior cruciate ligament (ACL) reconstruction surgery at the Centre 
Hospitalier Universitaire de Sherbrooke (CHUS) (Table 2). The protocol was reviewed and 
approved by the CHUS Ethics Committee (#11-122), and the biopsy was performed under 
the informed consent. Muscle samples (mean mass, 5.4±1.2g) were placed on ice in stérile 
tissue culture medium composed of Dulbecco’s modifïed eagle medium (DMEM) 
supplemented with 10% fetal bovine sérum (FBS) and 1% antibiotics, and immediately 
transferred to the laboratory.
Figure 4.1: Semitendinosus tendon with associated muscle tissue (arrowhead).
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Table 2: Summary of human muscle biopsies used for experiments
Sample No Sex Age (years) Weight (g)
M37 M 21 3.84
M38 F 37 3.23
M39 F 28 4.49
M41 M 24 6.30
M52 F 41 7.35
M58 M 36 7.35
M60 F 52 5.88
M63 M 21 5.72
M68 M 34 4.58
Average 32.7±8.1 5.4±1.2
4.2. Tissue préparation
Skeletal muscle samples were carefully dissected leaving them free of any tendon 
and/or fat tissues. They were then minced and digested with 1 mg/mL collagenase type I 
(Sigma) in DMEM containing 10% FBS, for 30 min at 37°C at a ratio o f 4g o f tissue for 
30ml of lmg/ml collagenase type I in medium. The tissue slurry was diluted with medium 
and passed through a 70-pm and then a 40-pm cell strainer (Becton Dickenson) prior to 
centrifugation (325xg, 6 min, 4°C). Cell pellets were resuspended in 8ml of fresh medium.
4.3. Cell culture
Primary human muscle derived adhèrent cells were grown in Mesencult-XF® 
medium (StemCell Technologies, Vancouver, Canada) supplemented with 1% antibiotics. 
This medium is referred to as ‘defined medium’. Collected cells were counted and allowed 
to attach in a 100-mm tissue culture plate coated with Mesencult-XF® attachment substrate 
(StemCell Technologies) for approximately 7 days without a medium change on day 4. The 
cells isolated from approximately 4g of tissue were left to adhéré in a single 100mm pétri 
dish. Roughly 7xl05 adhèrent cells were recovered per gram of tissue. At 80% confluence,
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cells were trypsinized, centrifuged (325xg, 6 min, 4°C) and resuspended in defined medium 
as passage 1 cells with fresh medium changes every 3-4 days. Cells were sub-cultured at a
-2 -y
density of 4x10 cells/cm .
Normal human dermal fibroblasts (NHDF) (ATCC, Manassas, VA, USA) were 
grown in DMEM supplemented with 10% FBS and 1% antibiotics in uncoated 100-mm 
tissue culture plates.
Fluman skeletal muscle myoblasts (HSMM) (Lonza, Allendale, NJ, USA) were 
cultured in Clonetics™ skeletal muscle cell growth media (Lonza, Allendale, NJ, USA) 
according to the manufacturer’s recommendation. Cells were passaged at 80% confluence.
4.4. Fluorescent-activated cell sorting of human muscle résident cells
First passage cells were detached with the Accutase™ Cell Detachment solution 
(BD Biosciences), centrifuged and resuspended in cold sorting buffer (PBS; ImM EDTA; 
25 mM HEPES pH 7.0; 1% FBS) at - lx lO 6 cells per ml. The cells were incubated for 20 
min. on ice with appropriate primary antibodies (Table 3) according to the manufacturer s’ 
instructions. During the cell sorting experiment live cells were distinguished from dead 
cells with the LIVE/DEAD® Violet Viability/Vitality Kit (Invitrogen). Fluorescence 
compensation was done using the BD CompBeads Set Anti-Mouse Ig, k  (BD Biosciences). 
Sorting was performed using a BD FACSAria™ cell sorter (BD Biosciences) equipped 
with four lasers, using a 100-pm nozzle at 20 psi. Sorting gates were defined based on 
unstained Controls. Analysis was performed using FlowJo 7.9 software (Treestar Inc., 
Ashland, OR, USA). A population of unsorted cells was also kept as a control. Unsorted 
and sorted fractions were then expanded in defined medium on coated tissue culture dishes.
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Table 3: Summary of primary antibodies used for flow cytometry
Antibody Clone Isotype Company
FITC anti-human CD90 5E10 MouseIgGl,K BD; 555 595
APC anti-human CD73 AD2 MouseIgGl.K BD; 560 847
PerCP-CyTM 5.5 266 Mouse BD; 560 819anti-human CD 105 IgGl, K
PE-Cy7 anti-human CD31 WM59 MouseIgGl eBioscience; 25-0319
PE anti-human CD34 581 Mouse IgG 1, K BD; 562 799
BV421 anti-human CD 140a aRl Mouse IgG2a, k BD; 562 799
N.B.: The dilution used for each antibody was made according to the m anufacturer’s instructions.
4.5. In vitro différentiation (ostéogénie, adipogénie and chondrogenic)
For adipogénie and ostéogénie assays, cells (passage 5 or 6) were seeded at a 
density o f 8 x 103 cells per well in 24-well collagen-coated plates in defined medium until 
the cells reached confluence, typically 4-5 days after seeding. The tissue culture grade 
plates were coated with 0.1 mg/ml rat-tail collagen type 1 (Millipore) for 2 hours and dried 
ovemight before plating.
For ostéogénie différentiation cells were stimulated with ostéogénie medium (see 
medium composition summarized in Table 3) for 21 days as described before with some 
modifications (Lecourt et al. 2010; Lee et al. 2010). Cells of the control group were 
cultured in DMEM supplemented with 5% horse sérum (HS). To assess mineralization, 
calcium deposits in cultures were stained with Alizarin Red-S (Sigma; 40mM pH 4.1) 
(Gregory et al. 2004).
For adipogénie différentiation, cells were first treated with an adipogénie induction 
medium for 72h, followed by 18 days o f white adipogénie growth medium, a protocol 
adapted from Vermette et al. (Vermette et al. 2007). Différentiation media was changed 
twice a week for 3 weeks. An Oil Red O solution (Sigma; 0.5% Oil red O in isopropyl
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alcohol) was used to detect triglycérides présent within lipid droplets o f mature adipocytes 
(Table 4).
The same protocol was used for brown adipocyte différentiation, with the exception 
of continuous ROS (Sigma) stimulation, adapted from Pisani et al. (Pisani et al. 2011), and 
only 11 days of brown adipocyte growth medium. BMP7 was also added to the adipogénie 
différentiation medium in order to détermine its capacity to induce brown versus white 
adipogenesis (Tseng et al. 2008; Schulz et al. 2011).
For chondrogenesis, chondrogenic culture medium consisting of serum-free DMEM 
containing lOpM dexamethasone (Sigma), 1% ITS+ (Wisent) and 1 Ong/ml TGFpl (Sigma) 
was added to ~2.5xl O5 cells (passage 5 or 6) in a stérile 15-ml tube which were pelleted by 
centrifugation at 350xg for 6 min at 4°C. It is important to add the chondrogenic medium 
before centrifugation, since the pellet formed after centrifugation could be resuspended by 
adding medium. Each pellet was cultured in 0.5pl o f media which was changed twice a 
week. The pellets were harvested on day 21, fixed in 4% phosphate buffered formalin, 
processed into paraffin wax, sectioned at 5pm and stained with Alcian blue (ACROS 
ORGANICS; 1% Alcian blue in 3% acetic acid) which stains the highly sulfated 
proteoglycans that characterize the cartilaginous matrix (Table 4).
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Table 4: Summary of the multilineage différentiation media composition
Lineage Basai medium Induction suppléments Assay
Ostéogénie DMEM, 5% HS 
1 % antibiotics
10 pg/ml ascorbic acid 
100 nM dexamethasone 
10 mM P-glycerophosphate
Alizarin red S
Chondrogenic DMEM,
1% antibiotics
10 pM dexamethasone 
1XITS
10 ng/ml TGFpi
Alcian blue
Adipogénie DMEM, 3% FBS 100 nM Insulin
Induction 1 % antibiotics 0.2 nM T3
1 pM dexamethasone
0.25 mM isobutyl 
methylxanthine
1 pM ROS
White DMEM, 10% FBS, 100 nM Insulin Oil Red O
adipogénie 1 % antibiotics 0.2 nM T3
growth 1 pM dexamethasone
Brown DMEM, 10% FBS, 100 nM Insulin
adipogénie 1 % antibiotics 0.2 nM T3
growth 1 pM dexamethasone 
1 pM ROS
Myofibroblastic DMEM, 2% HS, 
1 % antibiotics
25 ng/ml TGFpl aSMA
4.6. Clonal growth and différentiation
Clones o f the multipotent human muscle résident mesenchymal stromal cell 
(hmrMSCs: [CD73+CD105+CD90~]) were established by limiting dilution. Briefly, passage 
2 cells were suspended at a concentration o f less than 1 cell per 200 pl o f defined medium
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and plated in coated 96-well plates with 200 pl o f medium per well and incubated at 37°C 
and 5% CO2, with medium changes once a week. After 72h, wells with a single cell were 
identified. After 2-3 weeks, single cell-derived clones were treated with 0.25% trypsin and 
seeded into 48-well plates, and subsequently 24-well plates to expand into clonal progenies. 
Clonal progenies were transferred to 6-well plates upon confluence of approximately 80% 
and maintained with medium changes every 3-4 days.
4.7. RNA extraction
Total RNA was extracted using TRIzol® (Invitrogen) according to the 
manufacturer's instructions with a few modifications. The cells were rinsed with cold (4°C) 
PBS and then 500 pl o f TRIzol® was added to each sample. The cell lysate was recovered 
with a stérile cell scrapper and transferred to a microtube. Then, 100 pl o f chloroform was 
added and the samples were vigorously agitated by hand for 15 sec. and centrifuged 
(13.2K, 15 min., 4°C). The RNA was precipitated lh  at 4°C with isopropanol and 1 pg of 
glycogen, rinsed with ethanol and resuspended in RNAse-free water. The samples were 
kept at -80°C for up to one month.
The concentration o f RNA was determined by measuring the absorbance at 260nm, 
were 1 unit of absorbance (Abs) is equal to a concentration of 0.025 mg/ml (Commoner and 
Lipkin 1949; Kocsis et al. 2006). The A260/A280 ratio was calculated to ensure purity of 
the RNA. A ratio superior to 1.7 was considered acceptable.
4.8. Compiementary DNA and reverse transcription
The RNA (1 pg) was reverse-transcribed using the RT Superscript II kit 
(Invitrogen). Following the reaction, 60 pl of stérile water was added to each tube for a 
final concentration of 25 ng/pl o f cDNA.
4.9. Quantitative PCR (qPCR)
The reactions were prepared in a total volume of 20 pl with SYBR green master 
mix 2X (BioRad), 50 ng of cDNA (2pl) and 50 ng of each primer. The samples were then
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placed in the qPCR device (RotorGene 6000, Corbett Robotics, Eight Mile Plains, 
Australia) and the reactions executed with the following program: 10 min at 95°C; 40 
cycles of 40 seconds at 95°C and 40 seconds at 56°C. The dissociation curve (melting 
curve) was verified each time to ensure primer quality, such as specificity as well as the 
absence of primer-dimers. The results were analyzed using the 2~AACT relative 
quantification method normalized to the TATA-box binding protein (TBP). The primer sets 
are listed in Table 5 and were obtained from a previous study (Pisani et al. 2011).
Table 5: Primer sequences used for gene expression analysis
Gene Forward primer Reverse primer Accession No
PPARy AGCCTCATGAAGAGCCTTCCA TCCGGAAGAAACCCTTGCA NM005037
FABP4 TGTGCAGAAATGGGATGGAAA CAACGTCCCTTGGCTTATGCT NM 001442.2
ADIPOQ GCAGTCTGTGGTTCTGATTCCATAC GCCCTTGAGTCGTGGTTTCC NM 004797.3
UCP1 GTGTGCCCAACTGTGCAATG CCAGGATCCAAGTCGCAAGA NM021833
CI DE A GGCAGGTTCACGTGTGGATA GAAACACAGTGTTTGGCTCAAGA NM001279
TBP CACGAACCACGGCACTGATT TTTTCTTGCTGCCAGTCTGGAC NM003194
4.10. Immunofluorescence
Cells were fixed in 4% paraformaldéhyde (PFA) diluted in PBS (10 min at 4°C), 
blocked in PBS containing 10% goat sérum, 1% BSA, and 0.2% Triton®X-100, and then 
incubated with anti-Pax7 (1:3, DSHB), anti-UCPl antibody (1:800, H-150, Abcam) or anti- 
human a-smooth muscle actin (aSMA) antibody (1:100, 1A4, Cedarlane) for 90 min. at 
room température (RT). After several rinses in PBS-Tween-20 (0.1%), cells were incubated 
with either Alexa Fluor®488-conjugated goat anti-mouse IgG or Alexa Fluor®594- 
conjugated goat anti-rabbit IgG secondary antibody (1:1000, Invitrogen). Primary 
antibodies were omitted as a control. Cell nuclei were stained with DAPI reagent (Sigma- 
Aldrich) for 10 min after secondary antibody incubation. Indirect immunofluorescence was 
examined without counterstaining using an Axioskop 2 phase-contrast/epifluorescence 
microscope (Cari Zeiss, Inc., Thomwood, NY, USA) or using a DMIRE2 inverted 
microscope (Leica Microsystems). Photomicrographs were captured using a Retiga SRV
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cooled color digital caméra (Qimaging, Bumaby, Canada). The images were processed 
using Adobe Photoshop CS5 (Adobe suite).
4.11. Western blot analyses
Cells were lysed on ice in RIPA buffer (0.5% (v/v) NP-40, 0.1% (m/v) SDS, 150 
mM NaCl, 50m M Tris-HCl, pH 7.5) containing protease inhibitors (Complété™, Roche 
Molecular Biochemical). The homogenate was centrifuged 15 min at 4°C and the 
supematant containing the proteins recovered. The protein concentration was determined 
by the Bradford method (Bradford 1976) using bovine sérum albumin (BSA) as a standard 
protein.
The protein extracts (30 pg) were prepared in Laemmli loading buffer (0.5 M Tris- 
HCl, pH 6.8, glycerol, 10% (m/v) SDS, 0.01% (m/v) bromophenol blue, 10% (m/v) P- 
Mercapto-ethanol) and were separated by polyacrylamide gel electrophoresis (PAGE). 
Protein séparation was done at a constant voltage of 100V for 90 min. Then, the proteins 
were transferred to PVDF membranes (Millipore), previously activated in methanol, in 
transfer buffer (150 mM glycine, 20 mM Tris-base and 10% (v/v) methanol). The transfer 
was done at a constant voltage of 80V for two hours. The membranes were then rinsed 
three times in PBS-T (PBS with 0.1% (v/v) Tween20) and incubated with anti-UCPl 
(1:1000, 145-159, Abcam) and anti-GAPDH (1:1000, FL-335, Santa-Cruz) antibodies 
ovemight at 4°C. The membranes were again rinsed in PBS-T before being incubated with 
the secondary HRP (horseradish peroxidase) coupled antibody (1:5000; Amersham) at RT 
for one hour. After several rinses the membranes were exposed by chemiluminescence, 
with a homemade ECL solution (unpublished). This solution is a 1:1 mix of solution A and 
B. The solution A contains 10 ml o f Tris 0.1M pH 8.5, 50 pl of 90 mM coumaric acid in 
DMSO and 100 pl of 250 mM luminol in DMSO. The solution B is made up of 10 ml o f 
Tris 0.1 M pH 8.5 and 6 pl of 30% (v/v) hydrogen peroxide. Solutions A and B are 
combined and deposited on the membrane for 1 min. Biomax ML film (Kodak) is placed 
against the membranes in order to create an autoradiogram of the antibody binding sites, 
which is digitized. The bands were quantified by densitometry with the ImageJ software 
(version 1.46, National Institute of Health, USA) (Abramoff et al. 2004).
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4.12. Myofibroblastic différentiation
For myofibroblastic différentiation, cells (passages 3 to 6) were seeded at a density of 
4x103 cells per cm2 on collagen-coated plates (as described above) in defined medium until 
the cells reached 75% confluence, typically 2 days after seeding. Myofibroblastic 
différentiation medium consisted of DMEM, supplemented with 2% HS and 5 ng/ml or 25 
ng/ml o f recombinant human TGFpi (Sigma) as described elsewhere (Lee et al. 2010). For 
the négative control condition, the TGFJ31 was omitted (Table 4).
4.13. Collagen gel contraction assay
Cells grown in defined medium were trypsinized, centrifuged (325xg, 6 min, 4°C) and 
resuspended in DMEM supplemented with 0.5% FBS and kept on ice. 250 000 cells were 
resuspended in 500 pl of a 2 mg/ml collagen solution (rat tail collagen, Type 1, BD) 
according to manufacturées instructions. The cell-populated collagen solution was placed 
in 48-well plates (500 pl per well) and placed at 37°C for 30 min to induce gélation. 500pl 
of the appropriate induction medium was then added to each well (described above) and the 
cells were incubated in a humidified atmosphère at 37°C. After 48h o f incubation, cell 
populated collagen lattices were physically detached and allowed to float freely in the 
medium. The diameters of the collagen lattices were digitalized at several times points for 
up to 4 days and were measured using the ImageJ software (Abramoff et al. 2004).
4.14. Statistical Analysis
The values were expressed as mean +/- standard error o f the mean (SEM). Statistical 
analyses were performed using the paired /-tests for experiments comparing same cell lines 
from one experiment. Unpaired /-tests were used for the experiments comparing différent 
cell lines or the same cells from différent experiments. Power calculations were performed 
with a confidence interval o f 95%. The /?<0.05 values were considered statistically 
significant. Statistical analyses and graphies were carried out using the Prism 5.0 software 
(GraphPad Software Inc.).
5 . R e s u l t s
5.1. Enrichment strategy for human muscle résident mesenchymal stromal cells
5.1.1. Isolation and culture conditions
Freshly isolated human muscle résident cells were plated and cultured as adhèrent 
cells. In order to détermine the optimal growth medium, we cultured cells with a classic 
growth medium containing 10% FBS and another commercially available defined medium 
which did not contain sérum. Cells cultured in sérum or defined medium, reached -80%  
confluence on average within 21 and 7 days, respectively. The cells in defined medium 
maintained a rapid prolifération up to 7 passages, whereas the cells cultured in sérum 
medium proliferated at a significantly lower rate (Fig. 5.1 A). Furthermore, the cells from 
one donor did not proliferate in the sérum medium in PO. The majority o f cells cultured in 
both médiums displayed a regular spindle-like morphology (Fig. 5.1B) although a number 
of cells grown in the sérum medium were bigger in size with what appears to be stress 
fibers (Fig. 5.1 B).
-a— Defined #1 
■B— Defined #2 
Defined #3
Sérum #1 
Sérum #2
Time in culture (days)
Figure 5.1: Prolifération and morphology of adhèrent human muscle derived cells in 
sérum versus defined media
(A) Logarithmic cell growth population curve of adhèrent human skeletal muscle derived cells in 
sérum or defined medium (n=3;M52, M63 and M38). The cells from one donor (M38) did not 
proliferate in sérum medium. (B) Représentative phase-contrast images of human muscle derived
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cells in sérum or defined medium (scale bar, 500 ^m). The data are from cell lines derived from 3 
différent donors for sérum and defined medium.
S. 1.2. A sub-population o f human muscle-resident cells expresses stromal
progenitor markers
Adhèrent cells, enzymatically isolated from whole human skeletal muscle biopsies, 
were amplified in defined culture medium until passage 2. At this point, the cells were 
fractioned by FACS based on the differential expression of established mesenchymal 
(CD 105, CD73, CD90), hematopoietic (CD34) and endothélial (CD31) cell surface markers 
(Fig. 5.2A) (Dominici et al. 2006). To begin, hematopoietic and endothélial cells were 
excluded, by CD34' and CD31’ gating on viable cells. Then, an initial stromal subset was 
defined based on CD105+ and CD73+ expression, which was further separated into CD90" 
and CD90+ cells. These subpopulations represent respectively 11 ±8% and 41 ±2% o f the 
total viable cell population (Fig. 5.2B). Following the sort, the cells were continuously 
cultured in defined medium. The CD73+CD105+CD90' cell sub-population exhibits a 
similar spindle-like morphology in vitro, in contrast to the CD73+CD105+CD90+ cells 
which have an elongated shape (Fig. 5.2C).. Their aspect ratio of 3.2±0.7 and 8.4±2.8 
respectively support these observations (Annex IV). As expected, unsorted control cells 
displayed a heterogeneous morphology The expression of PDGFRa (CD 140a) was also 
evaluated by flow cytometry analysis during the sort (Fig. 5.2D). In total, 58±6% of cells 
expressed PDGFRa. Interestingly, the majority o f these cells ended up in the 
CD73+CD105+CD90' subset (93±3%), whereas the CD73+CD105+CD90+ subset only had 
17±1% expression of this mesenchymal marker (Fig. 5.2D).
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Figure 5.2: Flow cytometry sorting strategy of human skeletal muscle stromal cell 
subpopulations
(A) Enrichment timeline of the stromal progenitor population from human skeletal muscle via 
FACS. (B) Gating strategy of représentative population M38 to sort human muscle résident 
mesenchymal stromal cells (hmrMSCs). Cells were forward (FSC) and side-scatter (SSC) gated to 
exclude débris and doublets. Total live cells were gated based on calcein violet fluorescence (V450) 
and exclusion of the aqua dye (V500). Hematopoietic (CD34) and endothélial (CD31) cells were 
excluded from analysis. Two populations of CD73+CD105+ cells were sorted based on differential 
expression of CD90. The percentages of each cell population are shown in the panels and are 
expressed as the mean of six independent experiments (M37, M38, M39, M60, M63, M68). (C) The 
“CD90”  subpopulation has a spindle-shaped fïbroblast-like appearance whereas the “CD90” 
subpopulation has an elongated morphology as shown by phase contrast microscopy (scale bar, 
500pm). Représentative images from the M38 sample. (D) The distribution of PDGFRa is shown in 
a flow cytometry dot plot analysis. Total live cells are black, the CD73+CD105+CD90+ subset is 
shown in grey, whereas the CD73+CD105+CD90‘ subset is shown in blue. The percentage of 
PDGFRa positive cells in each of these cell populations is expressed as a mean of two independent 
experiments (M58, M68).
5.2. Différentiation potential of human muscle résident mesenchymal stromal cells
5.2.1. Only CD73+CD 105 CD9(f cells are multipotent in vitro
After sorting, the CD73+CD105+CD90' and CD73+CD105+CD90+ cell 
subpopulations were cultured under ostéogénie, adipogénie and chondrogenic culture 
conditions to compare their différentiation potentials. Unsorted cells were used as a control. 
Alizarin red S staining revealed that only unsorted and CD73+CD105+CD90' cell 
subpopulations effïciently differentiated into osteoblasts, shown by the formation of 
mineralized nodules (Fig. 5.3A). Alizarin Red S staining colored calcium deposits in red. 
However, CD73+CD105+CD90+ cells did demonstrate minimal mineralization.
Upon adipogénie induction the CD73+CD105+CD90" cells strongly differentiated into 
adipocytes, adopting a spherical shape and accumulating lipid droplets, confirmed by Oil 
red O staining (Fig. 5.3B). Isolated cells also demonstrated some adipogénie différentiation 
in the unsorted population, whereas no adipocytes were observed in the 
CD73+CD105+CD90+ cell population.
Pellet cultured CD73+CD105+CD90' cells in chondrogenic medium generated 
chondrocytes as indicated by tissue morphology and confirmed by Alcian blue staining.
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Unsorted cells display some chondrogenic capacity, while CD73+CD105+CD90+ cells 
display minimal différentiation (Fig. 5.3C).
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Figure 5.3: CD73+CD105+CD90' cells demonstrate superior ostéogénie, adipogénie and 
chondrogenic activity in vitro
CD73+CD105XD90' cells demonstrate superior ostéogénie, adipogénie and chondrogenic activity 
in vitro as compared to unsorted and CD73 CD105 CD90* cells. (A) Mineralized, multilayered 
nodules in cultures grown in ostéogénie medium, stained with alizarin red S (scale bar, 250pm). (B) 
Triglycérides in mature adipocytes were detected by oil red O staining (scale bar, 250pm). (C) 
Alcian blue positive cartilage in paraffin wax 5pm-sections of cell pellets grown in chondrogenic 
conditions (scale bar, lOOpm). Représentative images from sample M38 are shown. Each 
experiment was performed in triplicate with cells from three independent donors (M37, M38, M39 
and M41).
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5.2.2. Clonal progenies o f CD 73CD 105CD  9(T hmrMSCs are multipotent
To address the notion that hmrMSCs arise from a common progenitor, we isolated 
clones from the CD73+CD105+CD90' cell population to détermine their lineage 
commitment and différentiation potential. Table 6 provides preliminary results for the 
frequencies o f clonal progenies derived from two independent donors (M60 and M68). In 
total, 9 single-cell derived clonal populations were established from 576 plated wells by 
limiting dilution (< 1 cell/ well), representing a clonal effïciency of approximately 1.6%. O f 
these 9, 4 clonal progenies (-44%) differentiated into ail three lineages, notably ostéogénie, 
adipogénie and chondrogenic (Fig 5.4). Three clonal progenies (-33% ) displayed bipotent 
différentiation capabilities, differentiating towards the ostéogénie and adipogénie or the 
adipogénie and chondrogenic lineages, whereas one clonal population (-11% ) was 
unipotent and differentiated only towards the adipogénie lineage (Table 6).
Table 6: Différentiation potential of CD73+CD105+CD90- clones
Clones1 n Différentiation potential (%)
Yielded progenies 9 100%
Tripotent 4 44%
Bipotent 3 33%
Unipotent 1 11%
No différentiation 
1 ^  ' '
1 11%
576 hmrSCs were plated in total
The non-clonal parent cells (CD73+CD105+CD90) readily differentiated into ail 
three lineages (ostéogénie, adipogénie and chondrogenic). Similarly, the derived clones 
shown here (Fig 5.4) differentiated into osteocytes that produced a mineralized matrix 
shown by a positive alizarin red S staining, adipocytes that stained positive for Oil red O 
and mature chondrocytes which stain positive for Alcian blue. This preliminary clonal data 
suggests that human mrMSCs (CD73+CD105+CD90‘) contain cells that can differentiate 
into ail three lineages, a defining characteristic of mesenchymal stromal cells. Interestingly, 
1 of the 9 clones failed to differentiate at ail, probably because these cells were already
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terminally differentiated or senescent. More clonal dérivations are necessary to establish a 
représentative différentiation potential.
Ostéogénie Adipogénie Chondrogenic
200nm
Figure 5.4: Clonal progenies of CD73+CD105+CD90' cells are multipotent in vitro
To address the heterogeneity of typical cultures of stromal cells, we established single-cell derived 
clones by limiting dilution of the CD73~CD105+CD90‘ subset. The différentiation of a 
représentative clonal progeny (M60) towards the ostéogénie, adipogénie and chondrogenic lineages 
in vitro shows robust différentiation towards ail three lineages in comparison to the unstimulated 
control. Alizarin red S staining was used to detect calcium deposits (Scale bar, 1mm), oil red o 
staining colored lipid vacuoles (Scale bar, 1mm) and Alcian blue colored proteoglycans (Scale bar, 
200pm). A higher magnification of the chondrogenic pellet shows typical cartilage lacunes with 
chondrocytes inside a characteristic of efficient chondrogenic différentiation (Scale bar, 1 OOgm).
5.2.3. The effect o f  BMP9 on ostéogénie différentiation o f  human muscle derived
cells
We have previously shown that BMP-9 has a strong ostéogénie effect on mouse 
muscle résident stromal cells (Leblanc et al. 2011). We therefore carried out a comparative 
study to verify the ostéogénie potential o f BMP9 on ail three human muscle cell 
subpopulations. Under normal ostéogénie conditions, both the unsorted and 
CD73+CD105+CD90' subpopulations differentiated into mature osteoblasts, whereas the 
CD73+CD105+CD90+ subset displayed minimal mineralization, as expected (alizarin red S
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staining). The addition o f 2 nM of BMP9 to the complété ostéogénie media or to the 
ostéogénie media without dexamethasone decreased mineralization intensity in ail three 
subsets, most notably in the unsorted and CD73+CD105+CD90+ subsets (Fig. 5.5).
Unsorted CD73+CD105+ CD73+CD105+ 
CD90* CD90*
Unstimuiated
Ostéogénie
Ostéogénie 
+ 2nM BMP9
Ostéogénie 
Dexamethsone 
+ 2nM BMP9
Figure 5.5: Ostéogénie effect of BMP9 on human muscle résident cell subsets
Ostéogénie différentiation of hmrMSC subset by BMP9. These cells were treated with control 
media, ostéogénie media alone, or with 2 nM BMP9 or without dexamethasone and with 2nM 
BMP9 for 21 days. Mineralization was then observed by alizarin red S staining. Each experiment 
was performed in triplicate with cells from three independent donors (n=3; M37, M38 and M39). 
(Scale bar, 1 cm)
5.2.4. Decreased myogénie cells in the CD73+CD105+CD9(f subset
To détermine the distribution o f myogénie cells following the sort, passage 3 cells o f 
each subset were stained for the paired domain transcription factor Pax7 (Fig. 5.6A) which 
is specifically expressed by quiescent satellite cells and proliferating muscle progenitor 
cells (Seale et al. 2000). Initially, approximately 20±9% of unsorted cells expressed Pax7. 
After the sort, few Pax7+ cells were found in the CD73+CD105+CD90' subset (2±2%), 
whereas the CD73+CD105+CD90+ subset was significantly enriched in Pax7+ cells 
(40±12%) (Fig. 5.6B).
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Figure 5.6: Expression of Pax7 in human muscle cell stromal subsets
(A) Représentative fluorescent immunohistochemistry of Pax7+ cells in human muscle stromal 
subsets at passage 3 (M37); Pax7 (green) and nucléus (blue) (Scale bar, 250 pm). (B) Quantification 
of Pax7 cells (expressed as a mean ± SD) of three independent experiments (n=3; M36, M37 and 
M38). Significant différences (****/><0.0001; **.P<0.002).
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5.3. Other progenitor populations présent in human skeletal muscle
5.3.1. Prospective brown adipocyteprogenitors in the CD73 CD1Q5 CD9(Ï
subset
Schulz et al. identified inducible brown adipocyte progenitors residing in mouse 
skeletal muscle (Schulz et al. 2011). Furthermore, it has been previously shown that 
human multipotent adipose-derived stem cells (hMADS) were able to differentiate into 
white and brown adipocytes depending on the length of activation by ROS (Elabd et al. 
2009).
We analyzed the expression of classical adipogénie markers such as fatty acid 
binding protein 4 (FABP4), adiponectin (ADIPOQ) and peroxisome proliferator activated 
receptor gamma (PPARy) as well as a gene found to be highly expressed in mouse brite 
adipocytes: uncoupling protein 1 (UCP1). Gene expression was quantified at day 14 
following either 3 days or a continuous 14 days of ROS stimulation alongside the 
adipogénie growth media in hmrMSCs (CD105+CD73+CD90"). Ail classical adipogénie 
genes (FABP4, ADIPOQ and PPARy) were signifïcantly increased both under normal 
adipogénie conditions (ROS day 1 to 3) and continuous ROS stimulation up to day 14 
compared to the unstimulated control (Fig. 5.7A). Brite spécifie gene UCP1 was also 
signifïcantly increased following both 3 and 14 days o f ROS treatment (Fig. 5.7A).
In addition, significant increase in the brown-fat spécifie marker UCP1 protein was 
observed by immunofluorescence and by western blot in hmrSCs treated with ROS 
(regardless of the length of treatment) (Fig. 5.7B,C). UCP1 protein expression, normalized 
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was again signifïcantly increased 
in hmrSCs treated with ROS (Fig. 5.7C).
Moreover, it has also been shown that BMP7 induced the expression of brown-fat- 
selective genes, notably UCP1, in a mouse primary progenitor cells (Tseng et al. 2008). 
However BMP7 did not have any effect on UCP1 expression in hmrMSCs 
(CD105+CD73+CD90 ) ( Annex I).
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Figure 5.7: Rosiglitazone stimulâtes the expression of UCP1 in CD73+CD105+CD90'cells
(A) Quantitative RT-PCR of classical white and brown adipocyte genes with 0, 3 or 14 days of ROS 
treatment combined with standard adipogénie media. Genes were normalized to TATA-binding 
protein (TBP). Data are presented as a mean ± SEM (n=4; N=3; M38, M58 and M68). *P<0.015; 
**/,<0.004; ***/J<0.006; fcO.OOOl. (B) Représentative fluorescent immunohistochemistry of 
UCP1 in hmrMSCs at passage 5 (M68); UCP1 (red) and nucléus (DAPI, blue) (Scale bar, 250 pm). 
(C) Western blotting of UCP1 at 14 days following 0, 3 or 14 days of ROS stimulation and 
adipogénie media. Quantification of UCP1 protein expression normalized to GAPDH. Data are 
presented as a mean ± SEM (n=3; N=3; M38, M58 and M68). *P<0.035. Each experiment was 
performed at least three times with cells from three independent donors (M38, M58 and M68).
5.3.2. Unsorted muscle résident cells contain myofibroblastic cells.
Transforming growth factor (TGFpi) is a potent inducer of myofibroblastic 
différentiation (Desmouliere et al. 1993), most notably through the induction of alpha- 
smooth muscle actin (aSMA) expression, a hallmark of myofibroblast différentiation. We 
analyzed aSMA expression with TGFpi in unsorted muscle résident cells. Few untreated 
cells expressed aSMA, whereas following 5 ng/ml or 25 ng/ml o f TGFpl treatment a 
significant increase in aSMA+ cells was observed by immunofluorescence (Fig. 5.8A). In a 
collagen gel contraction model validated in normal human dermal fibroblast (NHDF) 
(Annex II), we found that TGFpl stimulation yielded significant contraction compared to 
the unstimulated control (Fig. 5.8B). Quantitative data confirmed that 25 ng/ml o f TGFpi 
stimulation yielded the most significant contraction (Fig. 5.8C).
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Figure 5.8: Myofibroblastic différentiation of adhèrent human muscle résident cells by TGFfll
(A) Représentative fluorescent immunohistochemistry of aSMA (red) and nucléus (DAPI, blue). 
Unsorted muscle résident cells at passage 3 expressed aSMA+ upon TGFJ31 treatment. Few cells 
expressed aSMA+ without TGFpi stimulation. (B) Collagen gel contraction assay showed that 
TGFpi treatment promoted significant contraction. (C) Quantitatively, no TGFpi stimulation 
yielded the least contraction. Stimulation of unsorted muscle résident cells by either 5 ng/ml or 25 
ng/ml TGFpi produced significant contraction compared to the untreated cells. Data represent mean 
± SEM. (n=3; N=2; M57 and M60) *P<0.02, **P<0.005, ***P<0.0008, ****^<0.0001.
6. D is c u s s io n
Adult skeletal muscle is capable of efficient régénération in response to a variety o f 
insults. However when régénération fails fibrosis, fatty degeneration and heterotopic 
ossification can ensue. Although the myogénie precursors responsible for régénération have 
been clearly elucidated, the identity o f the cells responsible for regenerative disorders such 
as fibrosis, fatty degeneration and heterotopic ossification in human skeletal muscle remain 
controversial. Identifying these cells in humans would help better understand their rôle in 
these pathologies and enable the development o f treatments. Furthermore muscle tissue 
represents an abundant, accessible, and replenishable source of adult stem cells for cell- 
based tissue engineering. A population of cells isolated from muscle exhibits both 
multipotentiality and self-renewal capabilities.
Currently, the study of human muscle-resident mesenchymal stromal cells 
(hmrMSCs) is complicated by the lack of knowledge of spécifie markers, their relatively 
low abundance, their heterogeneity and the lack o f a culture system that supports their 
multi-lineage différentiation. In this thesis, we have described an isolation technique based 
on the expression of spécifie mesenchymal stromal cell surface markers that allow the 
enrichment of a population of multipotent stromal progenitors with multilineage 
différentiation potential towards ostéogénie, adipogénie and chondrogenic lineages in vitro. 
In addition, we have identified culture conditions that promote their efficient expansion.
6.1. Defined culture conditions are suitable for human muscle-derived MSC
expansion
Culture conditions represent a key factor in the successful prolifération and 
maintenance of undifferentiated progenitor populations. Currently, there are numerous 
culture methods for MSCs, making standardization difficult since it has been shown that 
human MSC prolifération is highly dépendent on growth media (Apel et al. 2009). As 
animal-derived sérum is used ail cases, this is less than favourable due to the dramatic 
influence that the sérum lot may have on MSC behaviour at différent levels (prolifération,
58
différentiation and gene expression) (Shahdadfar et al. 2005) and, importantly, increasing 
inter-laboratory variability. Furthermore, in the context o f future clinical applications 
involving cultured human MSCs, regulatory agencies require higher safety standards for 
clinical-grade préparations, for safety as well as for immunologie reasons, in order to 
eliminate the possibility of responses against the sérum components in immune compétent 
récipients and the transfer of potential pathogens (ex. prions) (Horwitz et al. 2002).
Our results show that cultures of hmrMSCs can be initiated and maintained in 
serum-free, defined culture conditions (Fig 5.1 A). This is an important contribution to 
future clinical trials involving expanded hmrMSCs. Moreover, the prolifération rate was 
superior to standard sérum culture conditions (Fig 5.1A). Wherever time is limiting for 
MSC génération, this can be used to speed up the clinical-scale culture of these cells. In this 
context, defined medium may even reduce costs and the time needed for expansion of cells.
Typically, human MSCs isolated and expanded in classic serum-containing media 
are mostly spindle-shaped (or fusiform). The morphology (and size) o f human MSCs may 
also be dépendent upon culture conditions (ex. growth media and culture surface) (Qian and 
Saltzman 2004; Solchaga et al. 2005). In our experiments, cells in the sérum and the 
defined media had a similar spindle-shaped morphology, although many cells in the sérum 
medium appeared bigger in size (Fig. 5.1B). The presence of larger cells that contained 
visible stress fibers suggests cell senescence (Hayflick 1965; Ksiazek 2009). This 
compromises hmrMSC banking possibilities as well as their multipotency.
To further ensure the safety and suitability o f human muscle-derived cells for 
clinical applications, careful analysis o f potential genetic modifications should be carried 
out to evaluate their tumorogenicity (Sekiya et al. 2002; Stolzing and Scutt 2006; Wagner 
et al. 2010), since cells might be subjected to chromosomal modifications, due to extensive 
cell culture and expansion (Grigorian et al. 2010; Nikitina et al. 2011; Poloni et al. 2011; 
Wang et al. 2012).
59
6.2. MSC phenotypic markers can be used to identify mrMSCs
MSCs are commonly isolated by their capacity to adhéré to tissue-culture plastic 
and their immunological characteristics by a spécifie panel o f markers. Because, MSCs do 
not express known unique phenotypic markers, the International Society for Cellular 
Therapy proposed minimal criteria (Dominici et al. 2006) for defining MSCs, notably 
based on their phenotype. The phenotype définition requires the expression of CD73, CD90 
and CD 105, together with a lack of expression o f haematopoietic progenitor and 
endothélial cell markers (CD34), a leukocyte marker (CD45) and several others markers 
spécifie for other contaminating cell types.
We isolated a population of multipotent mesenchymal stromal progenitors from 
human skeletal muscle by FACS using known MSCs markers (CD73, CD 105 and CD90) as 
well as the négative expression of haematopoietic and endothélial markers (CD34 and 
CD31 respectively).
In the current literature, there is a controversy regarding the expression of CD90 as 
a marker of mesenchymal stromal cells. Numerous articles report cell populations with high 
expression levels to be multipotent MSCs (Dominici et al. 2006; Lecourt et al. 2010; 
Chung et al. 2013). On the other hand, several articles suggest CD90 expression to be a 
marker of fibroblastic cells. One group showed that séparation into CD90+ and CD90' 
subsets in a human primary culture resulted in fiinctionally distinct subpopulations 
(Koumas et al. 2003). Only CD90+ cells were capable o f myofibroblastic différentiation, 
whereas only CD90' cells differentiated into adipocytes, as determined by the accumulation 
of lipid droplets (Koumas et al. 2003). Also, it was shown that CD90+ fibroblast-like cells 
in mouse skeletal muscle produce the muscle basement membrane component laminin a2 
(Fukada et al. 2008), a rôle more often associated with fibroblasts than MSCs. Another 
group show that the élimination of CD90 expressing cells was an effective method for the 
élimination of contaminating fibroblasts from human primary cell cultures (Kisselbach et 
al. 2009).
Based on these results, two cellular subsets were isolated from the adhèrent fraction 
of muscle-derived cells: both, positively expressing CD73 and CD105, negatively
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expressing CD34 and CD31 and distinct only in their expression o f CD90 (Fig. 5.2B). Up 
until now, both subpopulations meet the criteria used to characterize mesenchymal stromal 
cells in culture. They also exhibit a more uniform morphology after the sort, suggesting a 
more homogeneous cell population (Fig. 5.2C). Interestingly, the CD73+CD105+CD90‘ 
subset was also on average 93% positive for the identified MSC marker PDGFRa (Fig. 5.2 
D). The co-expression of these known MSC markers in the same cellular subset may help 
better compare this novel muscle-resident cellular subset to others that have been identified. 
However, it is often difficult to compare populations identified in mice since certain 
markers do not have a human équivalent, for example the well identified Seal ). The use o f 
several markers also helps fraction the unsorted muscle résident adhèrent fraction into 
différent subsets with potentially différent progenitor populations. On that note, it would be 
interesting to analyse to expression of these markers at différent times, such as following 
the cell isolation before the cells are cultured. This would give us a better idea o f the 
marker profile o f these cells in vivo.
6.3. Human skeletal muscle-derived CD73+CD105+CD90‘ MSCs are multipotent in
vitro
The multilineage capabilities o f the unsorted and sorted human muscle-derived cells 
were tested using standard différentiation media (see section 4.5). Only the 
CD73+CD105+CD90' cell subpopulation displayed multipotency in vitro, including 
osteogenesis, adipogenesis, and chondrogenesis (Fig. 5.3A-C). At first glance, this resuit 
appears to go against the norm since the expression of CD90 is considered to be a marker 
of mesenchymal/stromal cells (Dominici et al. 2006). Indeed, the studies performed on 
human muscle-derived cells aimed to characterize the expression of stromal cell markers 
(CD90, CD73 and CD 105) in vitro through several passages but without the objective to 
enrich spécifie cell subpopulations. Therefore it is the first account o f the enrichment of a 
subpopulation expressing these markers in human skeletal muscle. Also, other studies 
expanded muscle-derived cells in sérum based medium (Mastrogiacomo et al. 2005; 
Lecourt et al. 2010) which can affect the phenotype o f the cells. Donor-to-donor 
heterogeneity can sometimes be a problem when human tissue is used. However, with our 
isolation and FACS-based enrichment method, reproducible multilineage différentiation
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results were obtained across ail the donors tested, suggesting that the chosen markers 
represent good targets for identifying mrMSCs in the adhèrent fraction of human muscle- 
derived cells.
Furthermore, the multilineage potential was strong up to passage 6 for ail the donors 
tested for ail three subpopulations (Fig. 5.3A-C) (M37, M38, M39 and M41). These donors 
represent 2 men and 2 women between the âges o f 21 and 37 years old. This suggests that 
gender and âge do not significantly affect the différentiation capabilities of the cells. 
However, our oldest donor was 52 years old. Therefore, we cannot say whether this method 
would be as efficient on muscle samples from an older group of donors.
The robust ostéogénie and chondrogenic potential o f the human skeletal muscle 
CD73+CD105+CD90' subpopulation has promising applications in cell-based thérapies. 
Segmentai bone loss resulting from traumatic injuries, surgical tumor removal, and 
reconstructive opérations leave a void that can be filled by using bone graft substitutes. 
Currently available treatments, including autologous or allogenic bone grafting, allografts 
supplemented with demineralized bone matrix or ostéogénie protein, and vascularized bone 
graft, are limited. The biological failure o f engraftment is common and is probably related 
to the reduced ostéogénie capacity o f the donor bone-forming cells (Wu et al. 2010).
On the basis of the in vitro observations that muscle derived MSCs can differentiate 
into osteoblast, many attempts have been made to use expanded MSCs for in vivo bone 
tissue repair. In various animal models, the transplantation of muscle-derived MSCs 
engineered to secrete ostéogénie protein leads to their différentiation into the ostéogénie 
lineage and the accelerated healing of a bone defect (Lee et al. 2000; Peng et al. 2002). 
Particularly promising for orthopaedic applications, especially for bone formation, is the 
use of natural or synthetic biomaterials as carriers for muscle MSC delivery. Muscle MSCs 
have been seeded on ECM scaffolds and then implanted in vivo into rat, subsequently 
participating in bone formation (Sun et al. 2005). Therefore hmrMSCs are a promising cell 
source for cellular bone repair, particularly in delayed and non-union fractures.
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On the flip side, this hmrMSC subpopulation may also represent the cellular 
component of HO. The ability to enrich these cells in culture may help us understand the 
factors and environmental eues that push these cells towards the ostéogénie fate. Therefore, 
these cells represent an important tool in better understanding such regenerative disorders. 
For example, hmrMSCs represent a more appropriate tool for the screening of putative HO 
inductors than murine-derived stem cells or human immortalized cell lines.
The chondrogenic capacity o f the human muscle CD73+CD105+CD90' cell 
subpopulation also has promising potential, seeing as articular cartilage has a limited 
capacity to heal itself, most likely due to its limited vascular supply. Currently, treatments 
for cartilage injury include abrasion arthroplasty, micro fracture, autologous chondrocyte 
implantation, and meniscal or osteochondral allografts (Minas and Nehrer 1997; Komarek 
et a l 2010). However, none of these treatments fully restores the articular cartilage defect. 
The chondrogenic différentiation potential of muscle derived MSCs after in vitro culture 
and in vivo transplantation has been extensively studied (Kuroda et a l 2006; Claros et al. 
2008). Adachi et al reported the comparable healing of cartilage defects treated with 
collagen gel containing either muscle derived cells or chondrocytes; this suggests that 
skeletal muscle contains cells that can aid cartilage repair (Adachi et a l  2002).
Hence, muscle derived MSCs may represent a good alternative to primary bone 
marrow MSCs for use in tissue engineering applications, because o f their availability and 
the relative ease of muscle cell isolation (Qu-Petersen et a l  2002). Importantly, unlike 
human bone marrow MSCs, hmrMSCs can be easily and safely harvested in large 
quantities with minimal morbidity. Also, the low concentration o f MSCs in the bone 
marrow requires the use o f specialized equipment to concentrate the MSCs and may still 
yield too few cells (Muschler et a l 2005).
6.4. Multipotent clonogenic assays with CD73+CD105+CD90‘ cells
The hmrMSC subpopulation (CD73+CD105+CD 90) displays robust multipotent 
capacity after enrichment. Nevertheless, the ostéogénie, chondrogenic and adipogénie 
potentials have to be fully examined at the clonal level. A clonogenic assay will further
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characterize the stem cell properties of this human skeletal muscle cell subpopulation and 
eliminate the possibility that the différent cell fates observed stem from a heterogeneous 
mixture of différent precursor cells. Therefore, CD73+CD105+CD90’ cell clones were 
obtained by limiting dilution. Of the 576 plated wells, 9 single-cell derived clonal 
populations were established, representing a little over 1% yield (Table 5) most likely due 
to the stress clonal culture puts on primary cells. This represents a clonal efficiency similar 
to that observed in other studies using human primary cells (Zheng et al. 2013). For 
example, in another study on human skeletal muscle-derived cells the average cloning 
efficiency was 1.04%, representing 6 clones derived from 576 single-cell seeded wells 
(Zheng et al. 2013). The results from our clonogenic assay showed that 4 out of 9 
CD73+CD105+CD90‘ clonal progenies possess strong ostéogénie, adipogénie and 
chondrogenic potential (Fig. 5.4). This experiment confirms our hypothesis that the 
CD73+CD105+CD90' subset contains cells capable o f differentiating towards ail three 
lineages.
6.5. BMP9 stimulation hinders ostéogénie différentiation in human muscle-derived
cells
As members o f the TGF(3 superfamily, BMPs play a critical rôle in skeletal 
development, bone formation, cellular différentiation, and stem cell biology (Attisano and 
Wrana 2002; Shi and Massague 2003; Luu et al. 2007). BMP9 is among the most 
ostéogénie BMPs, promoting osteoblastic différentiation of MSCs both in vitro and in vivo 
(Kang et al. 2004; Luu et al. 2007). Our group has previously shown that BMP9 has a 
strong osteoinductive influence on mouse mrSCs by increasing their AlkP activity and 
bone-specific marker expression (Leblanc et al. 2011). We therefore wanted to see if 
BMP9 would have the same osteoinductive effect on hmrMSCs. However, unlike in the 
mouse model, BMP9 appeared to reduce the ostéogénie ability o f hmrMSCs (Fig 5.5). 
Several characteristics of BMPs can explain this unexpected resuit. Perhaps the 
concentration of BMP9 used in vitro was inappropriate, either insufficient or too strong. It 
is a common property of members of the TGFP superfamily to express a bell-shaped 
concentration response curve (M et al. 1996).
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Furthermore, in our mouse model, BMP9 induced HO in vivo only in damaged 
muscle, compared to BMP2 (Leblanc et al. 2011), suggesting that perhaps another signal is 
necessary to induce the ostéogénie fate through BMP9 signalling. Also, HO development 
follows an endochondral ossification process (Shore and Kaplan 2010). Perhaps, BMP9 
may be a more potent inducer of chondrogenic différentiation, which latter develops into 
ostéogénie cells. In fact, BMP9 promûtes adipogenesis (Kang et al. 2009) and also up- 
regulates Sox9 expression to induce chondrogenic différentiation (Majumdar et al. 2001; 
Blunk et al. 2003). Overall, BMP9 has far-reaching effects beyond osteogenesis. It would 
be interesting to study the effect o f BMP9 on human mrMSCs in another différentiation 
pathway than the ostéogénie one.
6.6. Prospective brown adipocyte progenitors in the CD73+CD105+CD90' human
skeletal muscle subset
Recently, brown-fat progenitors have been identified in the skeletal muscle and 
white fat of humans (Crisan et al. 2008; Elabd et al. 2009; Schulz et al. 2011), providing 
the potential for increasing the oxidative capacity o f these tissues by targeting these 
endogenous precursor cells to differentiate in vivo into energy-dissipating brown 
adipocytes. Furthermore, brown-like adipocytes are found in white fat dépôts upon 
physiological or pharmacological stimulation and there is evidence that white adipocytes 
can be converted to brown-like fat cells (Tiraby et al. 2003; Cinti 2009). We have shown 
that hmrMSCs (CD73+CD105+CD90') are able to undergo efficient white adipocyte 
différentiation (Fig 5.3B) whereas the other cellular subsets (unsorted and 
CD73+CD105+CD90+) had very little to no adipogénie capabilities; we then undertook a 
comprehensive analysis o f the brown adipocyte potential of the already adipogénie 
CD73+CD105+CD90‘ precursor cells. A recent study described mouse “brite” adipocytes, 
thermogenic brown-like adipocytes, obtained upon chronic PPARy activation o f primary 
cultures of white adipocyte precursors (Petrovic et al. 2010). Another study in human 
adipose-derived cells showed that cells were able to differentiate into white and brown 
adipocytes depending on the length of activation o f PPARy by ROS (Elabd et al. 2009). 
Our observations show that hmrMSCs can differentiate into brite adipocytes following 
continuous ROS treatment. Following a prolonged stimulation of hmrMSCs, we denoted an
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increased expression of classical adipogénie genes such as FAB4, ADIPOQ and PPARy 
(Fig 5.7A), as well as the brown adipocyte marker UCP1 (Fig 5.7A). UCP1 expression was 
also increased at the protein level, although regardless o f the length of treatment with ROS 
(Fig. 5.7B,C). These results suggest that during adipogénie différentiation there is the 
coexistence o f white adipocytes and brown adipocytes due to the simultaneous increase o f 
markers for both cell types. Nonetheless, hmrMSCs represent a promising human cell 
model to analyze brown modulating signais that have been described in rodents. For 
example, it was observed in mouse models that BMP7 induced brown adipocyte 
différentiation (Tseng et al. 2008; Schulz et al. 2011). However, our preliminary results 
showed no effect on UCP1 expression in hmrMSCs (Annex I). Similar results were 
observed in human multipotent adipose-derived stem cell (Pisani et al. 2011), highlighting 
the importance of human cellular models to detect the discrepancies between species. 
Taken together, our data suggests that differentiated brown-like human skeletal muscle- 
derived MSCs are représentative of the so-called brite adipocytes recently described in 
mice (Petrovic et al. 2010) though significant différences are observed with regards to 
signaling eues favoring brown adipogenesis.
7. C o n c l u s io n  a n d  p e r s p e c t iv e s
The results o f this thesis have enabled, for the first time, the identification and 
enrichment of a hmrMSC population based on defïned culture conditions and spécifie MSC 
phenotypic markers. The isolation method we established is o f great interest due to its 
reproducibility on a technical standpoint. Inter-laboratory inconsistency is reduced thanks 
to the use of a defïned culture system. Furthermore, the cell surface markers chosen to 
isolate the population of interest seem well conserved regardless o f donor-to-donor 
variability. Indeed, the hmrMSC (CD73+CD105+CD90') subpopulation displays robust 
multipotency in vitro towards the ostéogénie, chondrogenic and adipogénie cell fates, and 
clonal progenies from this subpopulation are multipotent towards the ostéogénie, 
adipogénie and chondrogenic lineages.
These characteristics make these cells exciting tools to help better understand 
regenerative disorders such as HO and fatty degeneration, which are relatively common 
occurrences following various skeletal muscle traumas or chronic pathologies (ex. muscular 
dystrophy). Understanding the mechanisms that push these progenitors towards ostéogénie 
or adipogénie fates could help develop treatments to hait and perhaps prevent their 
progress. On the other hand, the multipotent potential o f  these cells can be hamessed to 
develop cellular thérapies in order to treat difficult bone loss as well as cartilage defects. 
These are just a few of the reasons that highlight to importance of developing a culture and 
isolation method for human muscle-derived MSCs, and even better one that is compatible 
with future clinical applications.
Skeletal muscle is an excellent tissue source for progenitor cells due to its 
abundance and ease o f access. Furthermore, skeletal muscle is a tissue with exceptional 
regenerative capacity, due to the presence of various progenitor populations, most notably 
satellite cells and mrMSCs. However, our experiments identified the presence of other 
progenitor populations. Brown-like adipocytes, expressing increased levels of UCP1, were 
identified in the hmrMSC subpopulation (CD73+CD105+CD9CT), suggesting the yet 
unidentified human brown adipocyte progenitors may be présent in this subpopulation.
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Furthermore, myofibroblastic cells expressing aSMA (Fig. 5.8A) and capable o f collagen- 
gel contraction (Fig. 5.8B) following TGFpl stimulation were identified in the adhèrent 
fraction of human skeletal muscle-derived cells. These preliminary results indicate the 
presence of myofibroblastic progenitors, whose précisé identity will be further studied in 
future experiments.
In summary, we have reported a reproducible isolation and enrichment method for 
hmrMSCs, using defïned culture conditions and spécifie MSC phenotypic markers. The 
enrichment o f this cell population will help us better understand the physiopathologic cell 
processes they participate in.
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Supplementary figure 1: UCP1 expression in muscle résident stromal cells with BMP7
Quantitative RT-PCR of brown fat marker UCP1 following adipogénie stimulation in combination 
with ROS and/or BMP7 treatment (expressed in days). Gene expressions were normalized to 
TATA-binding protein (TBP). Data are presented as a mean ± SEM (n=l ; M58). ****P<0.0001.
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Supplementary figure 2: NHDF collagen gel contraction model
Quantitatively, no TGFpi stimulation yielded the least contraction. Stimulation of normal human 
dermal fibroblast with 5 ng/ml of TGFpi produced significant contraction compared to the 
untreated cells. Data represent mean ± SEM. *P<0.02, **/><0.005, ****P<0.0001.
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Supplementary figure 3: Pax7 expression, ostéogénie and adipogénie différentiation of HSMM
(A) Représentative fluorescent immunohistochemistry of Pax7+ cells in commercial human skeletal 
muscle myoblast (HSMM) cell at passage 5; Pax7 (green) and nucléus (DAPI, blue) (Scale bar, 250 
pm). Under ostéogénie conditions HSMM display mineralized nodules, shown by alizarin red S 
staining (B), however no adipocytes formed under adipogénie conditions (C) (Scale bar, 1 mm).
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Supplementary figure 4: Aspect ratio comparison o f CD73+CD105+CD90‘ versus 
CD73+CD105+CD90+ cells
Phase contrast microscopy images of sorted populations showing représentative cell morphology of 
the CD73+CD105XD90' versus CD73+CD105+CD90+ cell subsets (Scale bar, 125pm). Quantitative 
aspect ratio analysis of cell morphology (n = 50; M38). Data represent mean ± SEM. **P<0.0021.
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Supplementary figure 5: Ostéogénie and adipogénie différentiation capabilities in vitro
CD73+CD105+CD90' cells demonstrate superior ostéogénie and adipogénie activity in vitro as 
compared to CD73+CD105+CD90+ cells. (A) Mineralized, multilayered nodules in unstimulated 
(Unstim.) or ostéogénie stimulated (Stim.) cultures, stained with alizarin red S (scale bar, 1cm). (B) 
Triglycérides in mature adipocytes were detected by oil red O staining (scale bar, 250pm). Images 
from the triplicate with sample M38 are shown here. Each experiment was performed in triplicate 
with cells from four independent donors (M37, M38, M39 and M41 ).
